<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1507245578
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2018
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        OTEZLA 30MG F.C.TAB
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        APREMILAST
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        56
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        1998.50
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="PATHEON INC" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            PATHEON INC
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 530]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Salehiya Trading Co.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Amgen Europe BV
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        L04AA32 
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>What Otezla is</strong></p><p>Otezla contains the active substance &lsquo;apremilast&rsquo;. This belongs to a group of medicines called phosphodiesterase 4 inhibitors, which help to reduce inflammation.</p><p>&nbsp;</p><p><strong>What Otezla is used for</strong></p><p>Otezla is used to treat adults with the following conditions:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Active psoriatic arthritis</strong> - if you cannot use another type of medicine called &lsquo;Disease-Modifying Antirheumatic Drugs&rsquo; (DMARDs) or when you have tried one of these medicines and it did not work.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Moderate to severe chronic plaque psoriasis</strong> - if you cannot use one of the following treatments or when you have tried one of these treatments and it did not work:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; phototherapy - a treatment where certain areas of skin are exposed to ultraviolet light</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; systemic therapy - a treatment that affects the entire body rather than just one local area, such as &lsquo;ciclosporin&rsquo;, &lsquo;methotrexate&rsquo; or &lsquo;psoralen&rsquo;.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Beh&ccedil;et&rsquo;s disease (BD) </strong>- to treat the mouth ulcers which is a common problem for people with this illness.</p><p>&nbsp;</p><p><strong>What psoriatic arthritis is</strong></p><p>Psoriatic arthritis is an inflammatory disease of the joints, usually accompanied by psoriasis, an inflammatory disease of the skin.</p><p>&nbsp;</p><p><strong>What plaque psoriasis is</strong></p><p>Psoriasis is an inflammatory disease of the skin, which can cause red, scaly, thick, itchy, painful patches on your skin and can also affect your scalp and nails.</p><p>&nbsp;</p><p><strong>What Beh&ccedil;et&rsquo;s disease is</strong></p><p>Beh&ccedil;et&rsquo;s disease is a rare type of inflammatory disease which affects many parts of the body. The most common problem is mouth ulcers.</p><p>&nbsp;</p><p><strong>H</strong><strong>o</strong><strong>w Otezla works</strong></p><p>Psoriatic arthritis, psoriasis and Beh&ccedil;et&rsquo;s disease are usually lifelong conditions and there is currently no cure. Otezla works by reducing the activity of an enzyme in the body called &lsquo;phosphodiesterase 4&rsquo;, which is involved in the process of inflammation. By reducing the activity of this enzyme, Otezla can help to control the inflammation associated with psoriatic arthritis, psoriasis and Beh&ccedil;et&rsquo;s disease, and thereby reduce the signs and symptoms of these conditions.</p><p>&nbsp;</p><p>In psoriatic arthritis, treatment with Otezla results in an improvement in swollen and painful joints, and can improve your general physical function.</p><p>&nbsp;</p><p>In psoriasis, treatment with Otezla results in a reduction in psoriatic skin plaques and other signs and symptoms of the disease.</p><p>&nbsp;</p><p>In Beh&ccedil;et&rsquo;s disease, treatment with Otezla reduces the number of mouth ulcers and can stop them completely. It can also reduce the associated pain.</p><p>&nbsp;</p><p>Otezla has also been shown to improve the quality of life in patients with psoriasis, psoriatic arthritis or Beh&ccedil;et&rsquo;s disease. This means that the impact of your condition on daily activities, relationships and other factors should be less than it was before.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>D</strong><strong>o not take Otezla:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are allergic to apremilast or any of the other ingredients of this medicine (listed in section 6).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are pregnant or think you may be pregnant.</p><p>&nbsp;</p><p><strong>Warnings and precautions</strong></p><p>Talk to your doctor or pharmacist before taking Otezla.</p><p>&nbsp;</p><p><strong>Depression and suicidal thoughts</strong></p><p>Tell your doctor before starting Otezla if you have depression which is getting worse with thoughts of suicide.</p><p>&nbsp;</p><p>You or your caregiver should also tell your doctor straight away of any changes in behaviour or mood, feelings of depression and of any suicidal thoughts you may have after taking Otezla.</p><p><u>&nbsp;</u></p><p><strong>Severe kidney problems</strong></p><p>If you have severe kidney problems, your dose will be different &ndash; see section 3.</p><p><u>&nbsp;</u></p><p><strong>If you are underweight</strong></p><p>Talk to your doctor while taking Otezla if you lose weight without meaning to.</p><p>&nbsp;</p><p><strong>Gut problems</strong></p><p>If you experience severe diarrhoea, nausea, or vomiting, you should talk to your doctor.</p><p>&nbsp;</p><p><strong>C</strong><strong>hildren and adolescents</strong></p><p>Otezla has not been studied in children and adolescents, therefore it is not recommended for use in children and adolescents aged 17 years and under.</p><p>&nbsp;</p><p><strong>Ot</strong><strong>her medicines and Otezla</strong></p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. This includes medicines obtained without a prescription and herbal medicines. This is because Otezla can affect the way some other medicines work. Also some other medicines can affect the way Otezla works.</p><p>&nbsp;</p><p>In particular, tell your doctor or pharmacist before taking Otezla if you are taking any of the following medicines:</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; rifampicin &ndash; an antibiotic used for tuberculosis</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; phenytoin, phenobarbital and carbamazepine - medicines used in the treatment of seizures or epilepsy</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; St John&rsquo;s Wort &ndash; a herbal medicine for mild anxiety and depression.</p><p>&nbsp;</p><p><strong>P</strong><strong>r</strong><strong>egnancy and breast-feeding</strong></p><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.</p><p>&nbsp;</p><p>There is little information about the effects of Otezla in pregnancy. You should not become pregnant while taking this medicine and should use an effective method of contraception during treatment with Otezla.</p><p>&nbsp;</p><p>It is not known if this medicine passes into human milk. You should not use Otezla while breast-feeding.</p><p>&nbsp;</p><p><strong>D</strong><strong>riving and using machines</strong></p><p>Otezla has no effect on the ability to drive and use machines.</p><p>&nbsp;</p><p><strong>Ot</strong><strong>ezla contains lactose</strong></p><p>Otezla contains lactose (a type of sugar). If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.</p><p>&nbsp;</p><p><strong>H</strong><strong>o</strong><strong>w much to take</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; When you first start taking Otezla, you will receive a &lsquo;treatment initiation pack&rsquo; which contains all the doses as listed in the table below.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The &lsquo;treatment initiation pack&rsquo; is clearly labelled to make sure you take the correct tablet at the correct time.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Your treatment will start at a lower dose and will gradually be increased over the first 6 days of treatment.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The &lsquo;treatment initiation pack&rsquo; will also contain enough tablets for another 8 days at the recommended dose (days 7 to 14).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The recommended dose of Otezla is 30&nbsp;mg twice a day after the titration phase is complete &ndash; one 30&nbsp;mg dose in the morning and one 30&nbsp;mg dose in the evening, approximately 12 hours apart, with or without food.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; This is a total daily dose of 60&nbsp;mg. By the end of day 6 you will have reached this recommended dose.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Once the recommended dose has been reached, you will only get the 30&nbsp;mg tablet strength in your prescribed packs. You will only ever need to go through this stage of gradually increasing your dose once even if you re-start treatment.</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:98%"><thead><tr><td><p><strong>D</strong><strong>ay</strong></p></td><td><p><strong>Morning Dose</strong></p></td><td><p><strong>E</strong><strong>vening Dose</strong></p></td><td><p><strong>Total Daily Dose</strong></p></td></tr></thead><tbody><tr><td><p><strong>D</strong><strong>ay 1</strong></p></td><td><p>10&nbsp;mg (pink)</p></td><td><p><strong>D</strong><strong>o not take a dose</strong></p></td><td><p>10&nbsp;mg</p></td></tr><tr><td><p><strong>D</strong><strong>ay 2</strong></p></td><td><p>10&nbsp;mg (pink)</p></td><td><p>10&nbsp;mg (pink)</p></td><td><p>20&nbsp;mg</p></td></tr><tr><td><p><strong>D</strong><strong>ay 3</strong></p></td><td><p>10&nbsp;mg (pink)</p></td><td><p>20&nbsp;mg (brown)</p></td><td><p>30&nbsp;mg</p></td></tr><tr><td><p><strong>D</strong><strong>ay 4</strong></p></td><td><p>20&nbsp;mg (brown)</p></td><td><p>20&nbsp;mg (brown)</p></td><td><p>40&nbsp;mg</p></td></tr><tr><td><p><strong>D</strong><strong>ay 5</strong></p></td><td><p>20&nbsp;mg (brown)</p></td><td><p>30&nbsp;mg (beige)</p></td><td><p>50&nbsp;mg</p></td></tr><tr><td><p><strong>D</strong><strong>ay 6 onwards</strong></p></td><td><p>30&nbsp;mg (beige)</p></td><td><p>30&nbsp;mg (beige)</p></td><td><p>60&nbsp;mg</p></td></tr></tbody></table><p>&nbsp;</p><p>People with severe kidney problems</p><p>If you have severe kidney problems then the recommended dose of Otezla is 30&nbsp;mg <strong>once a day (morning dose)</strong>. Your doctor will talk to you about how to increase your dose when you first start taking Otezla.</p><p>&nbsp;</p><p><strong>H</strong><strong>o</strong><strong>w and when to take Otezla</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Otezla is for oral use.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Swallow the tablets whole, preferably with water.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You can take the tablets either with or without food.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Take Otezla at about the same time each day, one tablet in the morning and one tablet in the evening.</p><p>&nbsp;</p><p>If your condition has not improved after six months of treatment, you should talk to your doctor.</p><p>&nbsp;</p><p><strong>I</strong><strong>f you take more Otezla than you should</strong></p><p>If you take more Otezla than you should, talk to a doctor or go to a hospital straight away. Take the medicine pack and this leaflet with you.</p><p>&nbsp;</p><p><strong>I</strong><strong>f you forget to take Otezla</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you miss a dose of Otezla, take it as soon as you remember. If it is close to the time for your next dose, just skip the missed dose. Take the next dose at your regular time.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not take a double dose to make up for a forgotten dose.</p><p>&nbsp;</p><p><strong>I</strong><strong>f you stop taking Otezla</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You should continue taking Otezla until your doctor tells you to stop.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not stop taking Otezla without talking to your doctor first.</p><p>&nbsp;</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>&nbsp;</p><p><strong>Serious side effects &ndash; depression and suicidal thoughts</strong></p><p>Tell your doctor straight away about any changes in behaviour or mood, feelings of depression, thoughts of suicide or suicidal behaviour (this is uncommon).</p><p>&nbsp;</p><p><strong>V</strong><strong>ery common side effects </strong>(may affect more than 1 in 10 people)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; diarrhoea</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; nausea</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; headache</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; upper respiratory tract infections such as cold, runny nose, sinus infection</p><p>&nbsp;</p><p><strong>C</strong><strong>ommon side effects </strong>(may affect up to 1 in 10 people)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; cough</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; back pain</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; vomiting</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling tired</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; stomach pain</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; loss of appetite</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; frequent bowel movements</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; difficulty sleeping (insomnia)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; indigestion or heartburn</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation and swelling of the tubes in your lungs (bronchitis)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; common cold (nasopharyngitis)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; depression</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; migraine</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; tension headache</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>U</strong><strong>ncommon side effects </strong>(may affect up to 1 in 100 people)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; rash</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; hives (urticaria)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; weight loss</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; allergic reaction</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; bleeding in the bowel or in the stomach</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; suicidal ideation or behaviour</p><p>&nbsp;</p><p><strong>Not known side effects</strong> (frequency cannot be estimated from the available data)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; severe allergic reaction (may include swelling of the face, lips, mouth, tongue, or throat that may lead to difficulty breathing or swallowing)</p><p>&nbsp;</p><p>If you are 65 years of age or older, you might have a higher risk of complications of severe diarrhoea, nausea and vomiting. If your gut problems become severe, you should talk to your doctor.</p><p>&nbsp;</p><p><strong>R</strong><strong>eporting of side effects</strong></p><p>If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. By reporting side effects, you can help provide more information on the safety of this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Keep this medicine out of the sight and reach of children.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not use this medicine after the expiry date which is stated on the blister or on the wallet or on the carton after EXP. The expiry date refers to the last day of that month.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not store above 30&deg;C.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not use this medicine if you notice any damage or signs of tampering to the medicine packaging.</p><p>&nbsp;</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>What Otezla contains</strong></p><p>The active substance is apremilast.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Otezla 10&nbsp;mg film-coated tablets: each film-coated tablet contains 10&nbsp;mg of apremilast.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Otezla 20&nbsp;mg film-coated tablets: each film-coated tablet contains 20&nbsp;mg of apremilast.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Otezla 30&nbsp;mg film-coated tablets: each film-coated tablet contains 30&nbsp;mg of apremilast.</p><p>&nbsp;</p><p>The other ingredients in the tablet core are cellulose microcrystalline, lactose monohydrate, croscarmellose sodium and magnesium stearate.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The film-coating contains poly (vinyl alcohol), titanium dioxide (E171), macrogol (3350), talc, iron oxide red&nbsp;(E172).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The 20&nbsp;mg film-coated tablet also contains iron oxide yellow (E172).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The 30&nbsp;mg film-coated tablet also contains iron oxide yellow (E172) and iron oxide black (E172).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                The Otezla 10 mg film-coated tablet is a pink, diamond shaped film-coated tablet with “APR” engraved on one side and “10” on the opposite side.
The Otezla 20 mg film-coated tablet is a brown, diamond shaped film-coated tablet with “APR” engraved on one side and “20” on the opposite side.
The Otezla 30 mg film-coated tablet is a beige, diamond shaped film-coated tablet with “APR” engraved on one side and “30” on the opposite side.

Pack sizes
•	The treatment initiation pack is a folding wallet containing 27 film-coated tablets: 4 × 10 mg tablets, 4 × 20 mg tablets and 19 × 30 mg tablets.
•	The one-month standard pack contains 56 × 30 mg film-coated tablets.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Marketing Authorisation Holder and Manufacturer</p><p>Amgen Europe B.V.</p><p>Minervum 7061</p><p>4817 ZK Breda</p><p>The Netherlands</p><p>&nbsp;</p><p>Site of Manufacture of the Drug Product</p><p>Patheon Inc.</p><p>111 Consumers Drive</p><p>Whitby, Ontario</p><p>L1N 5Z5,</p><p>Canada</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised in July 2021.
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL"><strong>ما هو دواء أوتيزلا</strong></p><p dir="RTL">يحتوي أوتيزلا على المادة الفعالة &quot;أبريميلاست&rlm;&quot;، التي تنتمي لمجموعة من الأدوية تسمّى مثبطات فوسفو داي إستريز&nbsp;٤، وهي تساعد في تخفيف الالتهاب.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>دواعي استعمال أوتيزلا</strong></p><p dir="RTL">يُستعمل أوتيزلا لعلاج البالغين الذين يعانون من الحالات المرضية التالية:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>التهاب المفاصل الصدافيّ</strong><strong> النشط</strong> - إذا كنت لا تستطيع استخدام نوع آخر من الأدوية التي تسمى &quot;الأدوية المضادة للروماتيزم المعدّلة لسير المرض (&rlm;DMARDs&rlm;)&rlm;&quot; أو عندما تكون قد جرّبت واحدا من هذه الأدوية ولم يُجدِ نفعا.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>الصداف اللويحي المزمن من المعتدل إلى الحادّ</strong> - إذا كنت لا تستطيع استخدام واحد من العلاجات التالية أو عندما تكون قد جرّبت واحدا من هذه العلاجات ولم يُجدِ نفعا:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; العلاج الضوئي - أي العلاج الذي تتعرض فيه مناطق معينة من الجلد للأشعة فوق البنفسجية</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; العلاج المجموعي - أي العلاج الذي يؤثر على الجسم كله بدلا من التأثير على منطقة واحدة فقط، مثل &quot;سيكلوسبورين&quot; أو &quot;ميثوتريكسات&rlm;&rlm;&quot; أو &quot;سورالين&quot;.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>مرض بهجت (</strong><strong>BD) </strong>- لعلاج قرح الفم التي تعد مشكلة شائعة للأشخاص المصابين بهذا المرض.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>ما هو التهاب المفاصل الصدافيّ</strong></p><p dir="RTL">التهاب المفاصل الصدافيّ هو مرض التهاب للمفاصل يترافق عادة مع الصداف (أو الصدفية) الذي هو مرض التهابي يصيب الجلد.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>ما هو الصداف اللويحي</strong></p><p dir="RTL">الصداف (أو الصدفية) هو مرض التهابي يصيب الجلد، ويمكن أن يسبب للجلد بقعا حمراء ومتقشرة وسميكة ومؤلمة ومثيرة للحكة، ويمكن أن يؤثر أيضا على فروة الرأس والأظافر.</p><p dir="RTL">&nbsp;</p><p dir="RTL">ما هو مرض بهجت</p><p dir="RTL">مرض بهجت هو نوع نادر من الأمراض الالتهابية التي تؤثر على عدد من أجزاء الجسم. والمشكلة الأكثر شيوعًا التي يسببها هي قرح الفم.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>كيف يعمل أوتيزلا</strong></p><p dir="RTL">مرض الصدفيّة، ومرض التهاب المفاصل الصدافيّ ومرض بهجت هي عادة حالات مرضية تبقى طوال الحياة وليس لها حاليا أي علاج شافي. يعمل أوتيزلا عن طريق الحدّ من نشاط إنزيم في الجسم اسمه &#39;فوسفو داي إستريز&nbsp;٤&quot; وهو يشارك في عملية الالتهاب. من خلال تقليص نشاط هذا الإنزيم، يمكن لأوتيزلا أن يساعد في السيطرة على الالتهابات المصاحبة للصدفية ولالتهاب المفاصل الصدافيّ ومرض بهجت، وبالتالي يحدّ من علامات هذه الحالات المرضية وأعراضها.</p><p dir="RTL">&nbsp;</p><p dir="RTL">في حالة التهاب المفاصل الصدافيّ، يؤدي العلاج بدواء أوتيزلا إلى تحسّن المفاصل المتورّمة والمؤلمة، ويمكن أن يحسّن وظائف جسمك بصورة عامة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">وفي حالة الصدفية، يؤدي العلاج بدواء أوتيزلا إلى تخفيف لويحات الجلد الصدفية وتخفيف العلامات والأعراض الأخرى للمرض.</p><p dir="RTL">&nbsp;</p><p dir="RTL">في حالة مرض بهجت، فإن العلاج باستخدام أوتيزلا يقلل من عدد قرح الفم ويمكنه إيقافها بشكل كامل. يمكنه كذلك تقليل الألم المصاحب لها.</p><p dir="RTL">&nbsp;</p><p dir="RTL">وقد تبيّن أيضا أن أوتيزلا يحسّن نوعية الحياة لدى المرضى الذين يعانون من الصدفية أو التهاب المفاصل الصدافيّ أو مرض بهجت. وهذا يعني أن تأثير حالتك المرضية على الأنشطة اليومية والعلاقات وعوامل أخرى يجب أن يصبح أقل مما كان عليه من قبل.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تتناول أوتيزلا في الحالات التالية:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كانت لديك حساسية ضد أبريميلاست &rlm;&rlm;أو أي من المكونات الأخرى لهذا الدواء (المدرجة في الفقرة&nbsp;٦).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنتِ امرأة حاملا أو تعتقدين أنك قد تكونين حاملا.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>التحذيرات والاحتياطات</strong></p><p dir="RTL">تحدث إلى طبيبك أو إلى الصيدلي الخاص بك قبل أن تتناول أوتيزلا.</p><p dir="RTL">&nbsp;</p><p dir="RTL">الاكتئاب والأفكار الانتحارية</p><p dir="RTL">أخبر طبيبك قبل بدء أوتيزلا إذا كنت تعاني من تفاقم الاكتئاب وتراودك أفكار بالانتحار.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يجب عليك أو على مقدم الرعاية الخاص بك أيضا إبلاغ طبيبك مباشرة بأي تغيرات في السلوك أو الحالة المزاجية أو الشعور بالاكتئاب وأي أفكار انتحارية قد تظهر لديك بعد تناول أوتيزلا.</p><p dir="RTL"><u>&nbsp;</u></p><p dir="RTL">مشاكل حادة في الكلى</p><p dir="RTL">إذا كانت لديك مشاكل حادة في الكلى، فسوف تختلف جرعتك - انظر القسم&nbsp;٣.</p><p dir="RTL"><u>&nbsp;</u></p><p dir="RTL"><strong>إذا كنت تعاني من نقص الوزن</strong></p><p dir="RTL">تحدث إلى طبيبك أثناء تناول أوتيزلا إذا نقص وزنك من دون أن تقصد ذلك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">مشاكل في الأمعاء</p><p dir="RTL">إذا كنت تعاني من الإسهال الشديد أو الغثيان أو القيء، فعليك التحدث مع طبيبك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأطفال والمراهقون</strong></p><p dir="RTL">لم تتم دراسة دواء أوتيزلا لدى الأطفال والمراهقين، وبالتالي فمن غير المستحسن استعماله من قبل الأطفال والمراهقين الذين تبلغ أعمارهم ١٧&nbsp;سنة أو أقل.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>أدوية أخرى وأوتيزلا</strong></p><p dir="RTL">قم بإبلاغ طبيبك أو الصيدلي إذا كنت تتناول، أو تناولت مؤخرا، أو تنوي تناول أي أدوية أخرى. وهذا يشمل الأدوية التي تحصل عليها بدون وصفة طبية وكذلك الأدوية العشبية. والسبب في ذلك هو أن أوتيزلا يمكن أن يؤثر على الطريقة التي تعمل بها بعض الأدوية الأخرى. وكذلك، يمكن أن تؤثر بعض الأدوية الأخرى على الطريقة التي يعمل بها أوتيزلا.</p><p dir="RTL">&nbsp;</p><p dir="RTL">وعلى وجه الخصوص، أخبر طبيبك أو الصيدلي قبل تناول أوتيزلا إذا كنت تتناول أيا من الأدوية التالية:</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ريفامبيسين &rlm;&rlm;- وهو مضاد حيوي يستخدم لمرض السل</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فينيتوين &rlm;&rlm;وفينوباربيتال &rlm;&rlm;وكاربامازيبين &rlm;&rlm;- وهي أدوية تُستعمل في علاج النوبات أو الصرع</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نبتة سانت جون - وهي دواء عشبي لحالات القلق والاكتئاب المعتدلة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الحمل والرضاعة الطبيعية</strong></p><p dir="RTL">إذا كنت حاملا أو ترضعين طبيعيا، أو تعتقدين أنك حاملا أو تخططين للحمل، من الضروري إخبار طبيبك أو الصيدلي قبل تناول هذا الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL">هناك القليل من المعلومات حول آثار أوتيزلا في حالة الحمل. يجب ألا تصبحي حاملا أثناء تناولكِ هذا الدواء، وينبغي أن تستعملي وسيلة فعالة لمنع الحمل أثناء العلاج بأوتيزلا.</p><p dir="RTL">&nbsp;</p><p dir="RTL">ومن غير المعروف ما إذا كان هذا الدواء يمرّ إلى لبن الأم. عليكِ عدم استعمال أوتيزلا أثناء فترة الرضاعة الطبيعية.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>قيادة السيارات واستخدام الآلات</strong></p><p dir="RTL">ليس لأوتيزلا أي تأثير على القدرة على القيادة واستخدام الآلات.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>يحتوي أوتيزلا على اللاكتوز</strong></p><p dir="RTL">يحتوي أوتيزلا على اللاكتوز (وهو نوع من السكر). إذا قال لك طبيبك أنك تعاني من عدم تحمل بعض السكريات، فتواصل مع طبيبك قبل تناول هذا الدواء.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">تناول دائما هذا الدواء حسب تعليمات طبيبك بشكل دقيق. إستشر طبيبك أو الصيدلي إذا كنت غير متأكد.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>كمية الدواء التي يجب تناولها</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عندما تبدأ بتناول أوتيزلا لأول مرة، سوف تتلقى &quot;عبوة بدء العلاج&quot; التي تتضمن كل الجرعات كما هو موضح في الجدول أدناه.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &quot;عبوة بدء العلاج&quot; موسومة بعلامات واضحة للتأكد من تناول الأقراص الصحيحة في الوقت الصحيح.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سيبدأ علاجك بجرعة منخفضة، وستتم زيادتها تدريجيا خلال فترة الـ ٦&nbsp;أيام الأولى من العلاج.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تحتوي &quot;عبوة بدء العلاج&quot; أيضا على كمية من الأقراص تكفي لفترة ٨&nbsp;أيام أخرى حسب الجرعة الموصى بها (من اليوم&nbsp;٧ إلى اليوم&nbsp;١٤).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الجرعة الموصى بها لأوتيزلا هي ٣٠&nbsp;ملغ مرتين في اليوم بعد استكمال مرحلة المعايرة &ndash; بجرعة ٣٠&nbsp;ملغ في الصباح وجرعة ٣٠&nbsp;ملغ أخرى في المساء، بحيث تفصلهما فترة ١٢&nbsp;ساعة تقريبا، وذلك بالتزامن مع تناول الطعام أو بدونه.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; هذه جرعة إجمالية يومية قدرها ٦٠&nbsp;ملغ. وبحلول نهاية اليوم&nbsp;٦ ستكون قد وصلت إلى الجرعة الموصى بها.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بمجرد أن تصل إلى الجرعة الموصى بها، سوف تحصل على عبواتك الموصوفة بأقراص من عيار ٣٠&nbsp;ملغ فقط. ولن تحتاج للمرور بهذه المرحلة التمهيدية التي تزيد فيها الجرعة تدريجيا إلا مرة واحدة فقط، حتى ولو بدأت فترة علاج جديدة.</p><p dir="RTL">&nbsp;</p><table dir="rtl" border="0" cellspacing="0" cellpadding="0" style="width:98%"><thead><tr><td><p dir="RTL"><strong>اليوم</strong></p></td><td><p dir="RTL"><strong>جرعة الصباح</strong></p></td><td><p dir="RTL"><strong>جرعة المساء</strong></p></td><td><p dir="RTL"><strong>الجرعة الإجمالية اليومية</strong></p></td></tr></thead><tbody><tr><td><p dir="RTL"><strong>اليوم&nbsp;١</strong></p></td><td><p dir="RTL">١٠&nbsp;ملغ (وردي)</p></td><td><p dir="RTL"><strong>لا تتناول جرعة</strong></p></td><td><p dir="RTL">١٠&nbsp;ملغ</p></td></tr><tr><td><p dir="RTL"><strong>اليوم&nbsp;٢</strong></p></td><td><p dir="RTL">١٠&nbsp;ملغ (وردي)</p></td><td><p dir="RTL">١٠&nbsp;ملغ (وردي)</p></td><td><p dir="RTL">٢٠&nbsp;ملغ</p></td></tr><tr><td><p dir="RTL"><strong>اليوم&nbsp;٣</strong></p></td><td><p dir="RTL">١٠&nbsp;ملغ (وردي)</p></td><td><p dir="RTL">٢٠&nbsp;ملغ (بنيّ)</p></td><td><p dir="RTL">٣٠&nbsp;ملغ</p></td></tr><tr><td><p dir="RTL"><strong>اليوم&nbsp;٤</strong></p></td><td><p dir="RTL">٢٠&nbsp;ملغ (بنيّ)</p></td><td><p dir="RTL">٢٠&nbsp;ملغ (بنيّ)</p></td><td><p dir="RTL">٤٠&nbsp;ملغ</p></td></tr><tr><td><p dir="RTL"><strong>اليوم&nbsp;٥</strong></p></td><td><p dir="RTL">٢٠&nbsp;ملغ (بنيّ)</p></td><td><p dir="RTL">٣٠&nbsp;ملغ (بيج)</p></td><td><p dir="RTL">٥٠&nbsp;ملغ</p></td></tr><tr><td><p dir="RTL"><strong>اليوم&nbsp;٦ وما بعده</strong></p></td><td><p dir="RTL">٣٠&nbsp;ملغ (بيج)</p></td><td><p dir="RTL">٣٠&nbsp;ملغ (بيج)</p></td><td><p dir="RTL">٦٠&nbsp;ملغ</p></td></tr></tbody></table><p dir="RTL">&nbsp;</p><p dir="RTL">بالنسبة إلى من يعانون مشاكل حادة في الكلى</p><p dir="RTL">إذا كانت لديك مشاكل حادة في الكلى، فإن الجرعة الموصى بها من أوتيزلا هي ٣٠&nbsp;ملغ <strong>مرة واحدة في اليوم (جرعة الصباح)</strong>. وسيتحدث إليك طبيبك عن كيفية زيادة جرعتك عندما تبدأ بتناول أوتيزلا لأول مرة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>كيف ومتى يتم تناول أوتيزلا</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إن أوتيزلا معدّ للتناول عن طريق الفم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قم بابتلاع الأقراص كلها، ويفضّل ابتلاعها مع الماء.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بإمكانك أن تتناول الأقراص بالتزامن مع تناول الطعام أو بدونه.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تناول أوتيزلا في نفس الموعد تقريبا كل يوم، بقرص واحد في الصباح وقرص واحد في المساء.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا لم تتحسن حالتك بعد فترة ستة أشهر من العلاج، فعليك إخبار طبيبك بذلك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>في حالة الإفراط في تناول أوتيزلا</strong></p><p dir="RTL">في حالة الإفراط في تناول أوتيزلا، تحدّث إلى طبيب أو اذهب إلى المستشفى على الفور. خذ معك عبوة الدواء وهذه النشرة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>في حالة نسيان</strong><strong> تناول أوتيزلا</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا فاتتك جرعة من أوتيزلا، فقم بتناولها حالما تتذكرها. وإذا كان ذلك قريبا من موعد تناول جرعتك التالية، فقم بتجاوز الجرعة المنسية. ثم تناول الجرعة التالية في موعدها المنتظم الموصوف لك.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تتناول جرعة مضاعفة للتعويض عن الجرعة المنسية.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا توقفت عن تناول أوتيزلا</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يجب عليك الاستمرار في تناول أوتيزلا إلى أن يطلب منك الطبيب التوقف عن تناوله.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تتوقف عن تناول أوتيزلا بدون استشارة طبيبك أولا.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كانت لديك أي أسئلة أو استفسارات أخرى حول استعمال هذا الدواء، فاسأل طبيبك أو الصيدلي.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل كافة الأدوية، يمكن لهذا الدواء أن يسبب آثارا جانبية، رغم أنها لا تظهر لدى كافة المرضى.</p><p dir="RTL">&nbsp;</p><p dir="RTL">الآثار الجانبية الخطيرة - الاكتئاب والأفكار الانتحارية</p><p dir="RTL">أخبر طبيبك مباشرة بشأن أي تغيرات في السلوك أو الحالة المزاجية أو الشعور بالاكتئاب أو أي أفكار انتحارية أو سلوك انتحاري (وهذا غير شائع).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الآثار الجانبية الشائعة جدا</strong> (قد تؤثر على أكثر من&nbsp;١ عن كل ١٠&nbsp;أشخاص)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإسهال</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الغثيان</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الصداع</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدوى الجهاز التنفسي العلويّ، مثل الزكام والرشح (سيلان الأنف) والتهاب الجيوب الأنفية</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الآثار الجانبية الشائعة</strong> (قد تؤثر إلى حدود&nbsp;١ عن كل ١٠&nbsp;أشخاص)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; السعال</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في الظهر</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; القيء</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شعور بالتعب</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في المعدة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان الشهية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغوّط متكرر أكثر من المعتاد</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة في النوم (الأرق)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عسر الهضم أو الشعور بحرقة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب وتورم في أنابيب الرئتين (التهاب الشعب الهوائية)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نزلات البرد (التهاب البلعوم الأنفي)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الاكتئاب</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الصداع النصفي</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الصداع الناتج عن التوتر</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الآثار الجانبية غير الشائعة</strong> (قد تؤثر إلى حدود&nbsp;١ عن كل ١٠٠&nbsp;شخص)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شَرَى (الارتكاريا)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نقص الوزن</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعل تحسّسي</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نزيف في الأمعاء أو في المعدة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التفكير أو السلوك الانتحاري</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الآثار الجانبية غير المعروفة</strong> (لا يمكن تقدير التكرار بناء على المعلومات المتاحة)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعل &nbsp;تحسسي حاد (قد يشمل حالات تورم في الوجه أو الشفتين أو الفم أو اللسان أو الحلق، ما قد يؤدي إلى صعوبة في التنفس أو البلع)</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كان عمرك ٦٥&nbsp;سنة أو أكثر، فقد يكون لديك خطر أكبر من مضاعفات الإسهال الشديد والغثيان والقيء. إذا أصبحت مشاكل الأمعاء حادة، فينبغي أن تتحدث إلى طبيبك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الإبلاغ عن الآثار الجانبية</strong></p><p dir="RTL">إذا تعرضت لأي آثار جانبية، يرجى إبلاغ طبيبك أو الصيدلي أو الممرض(ة). ويشمل ذلك أي آثار جانبية محتملة غير مدرجة في هذه النشرة. من خلال الإبلاغ عن الآثار الجانبية، يمكنك أن تساعد في توفير مزيد من المعلومات حول سلامة هذا الدواء.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يُحفظ هذا الدواء بعيدا عن مرأى ومتناول الأطفال.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تستعمل هذا الدواء بعد تاريخ انتهاء الصلاحية المذكور على نفطة الدواء أو على المحفظة أو على علبة الأقراص بعد كلمة &quot;EXP&rlm;&quot;&rlm;. ويشير تاريخ انتهاء الصلاحية إلى آخر يوم من ذلك الشهر.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يُحفظ في درجات حرارة لا تتعدّى ٣٠&nbsp;درجة مئوية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تستعمل هذا الدواء إذا لاحظت أي تلف لعلبة الدواء أو أي علامات للعبث بها.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تتخلّص من أي أدوية عن طريق مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي عن طريقة التخلص من الأدوية التي لم تعد تستعملها. هذه الإجراءات ستساعد في حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>ما الذي يحتوي عليه أوتيزلا</strong></p><p dir="RTL">المادة الفعالة هي أبريميلاست&rlm;&rlm;.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أقراص أوتيزلا المغلفة عيار ١٠&nbsp;ملغ: كل قرص مغلف يحتوي على ١٠&nbsp;ملغ من أبريميلاست.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أقراص أوتيزلا المغلفة عيار ٢٠&nbsp;ملغ: كل قرص مغلف يحتوي على ٢٠&nbsp;ملغ من أبريميلاست.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أقراص أوتيزلا المغلفة عيار ٣٠&nbsp;ملغ: كل قرص مغلف يحتوي على ٣٠&nbsp;ملغ من أبريميلاست.</p><p dir="RTL">&nbsp;</p><p dir="RTL">المكونات الأخرى في باطن القرص هي السليولوز البلوري المكرويّ، واللاكتوز الأحادي الماء، وكروسكارميلوز الصوديوم، وستيرات المغنيزيوم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يحتوي غلاف القرص على بولي (فينيل الكحول) وثاني أكسيد التيتانيوم (١٧١&rlm;&lrm;E&rlm;)، وماكروغول (٣٣٥٠)، وتالك، وأكسيد الحديد الأحمر (١٧٢&rlm;&lrm;E&rlm;).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; القرص المغلف عيار ٢٠&nbsp;ملغ يحتوي أيضا على أكسيد الحديد الأصفر (١٧٢&rlm;&lrm;E&rlm;).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; القرص المغلف عيار ٣٠&nbsp;ملغ يحتوي أيضا على أكسيد الحديد الأصفر (١٧٢&rlm;&lrm;E&rlm;)، وأكسيد الحديد الأسود (١٧٢&rlm;&lrm;E&rlm;).</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>الشكل الخارجي لأوتيزلا ومحتويات العبوة</strong></p><p dir="RTL">قرص أوتيزلا المغلف عيار ١٠&nbsp;ملغ هو قرص مغلف ذو لون وردي وشكل ألماسي، مع كلمة &quot;APR&quot; محفورة على أحد جانبيه والرقم&nbsp;&quot;١٠&quot; على الجانب الآخر.</p><p dir="RTL">قرص أوتيزلا المغلف عيار ٢٠&nbsp;ملغ هو قرص مغلف ذو لون بنيّ وشكل ألماسي، مع كلمة &quot;APR&quot; محفورة على أحد جانبيه والرقم &quot;٢٠&quot; على الجانب الآخر.</p><p dir="RTL">قرص أوتيزلا المغلف عيار ٣٠&nbsp;ملغ هو قرص مغلف ذو لون بيج وشكل ألماسي، مع كلمة &quot;APR&quot; محفورة على أحد جانبيه والرقم&nbsp;&quot;٣٠&quot; على الجانب الآخر.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>أحجام العبوات</u></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عبوة بدء العلاج هي محفظة قابلة للطيّ تحتوي على ٢٧&nbsp;قرصا مغلفا: ٤&nbsp;أقراص عيار ١٠&nbsp;ملغ و٤&nbsp;أقراص عيار٢٠&nbsp;ملغ و١٩&nbsp;قرصا عيار ٣٠&nbsp;ملغ.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; العبوة العادية لمدة شهر واحد تحتوي على ٥٦&nbsp;قرصا مغلفا عيار ٣٠&nbsp;ملغ.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">صاحب ترخيص التسويق والجهة المصنعة</p><p dir="RTL">‪Amgen Europe B.V.</p><p dir="RTL">Minervum 7061</p><p dir="RTL">4817&nbsp;ZK Breda</p><p dir="RTL">هولندا</p><p dir="RTL">&nbsp;</p><p dir="RTL">موقع تصنيع المُنتج الدوائي</p><p dir="RTL">‪Patheon Inc.</p><p dir="RTL">111&nbsp;Consumers Drive</p><p dir="RTL">‪Whitby, Ontario</p><p dir="RTL">L1N&nbsp;5Z5,</p><p dir="RTL">كندا</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تمّت آخر مراجعة لهذه النشرة في يوليو ٢٠٢١.
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Otezla 10 mg film-coated tablets
Otezla 20 mg film-coated tablets
Otezla 30 mg film-coated tablets

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Otezla 10 mg film-coated tablets

Each film-coated tablet contains 10 mg of apremilast.

Excipient(s) with known effect
Each film-coated tablet contains 57 mg of lactose (as lactose monohydrate).

Otezla 20 mg film-coated tablets

Each film-coated tablet contains 20 mg of apremilast.

Excipient(s) with known effect
Each film-coated tablet contains 114 mg of lactose (as lactose monohydrate).

Otezla 30 mg film-coated tablets

Each film-coated tablet contains 30 mg of apremilast.

Excipient(s) with known effect
Each film-coated tablet contains 171 mg of lactose (as lactose monohydrate).

For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film-coated tablet (tablet).

Otezla 10 mg film-coated tablets

Pink, diamond shaped 10 mg film-coated tablet of 8 mm length with “APR” engraved on one side and “10” on the opposite side.

Otezla 20 mg film-coated tablets

Brown, diamond shaped 20 mg film-coated tablet of 10 mm length with “APR” engraved on one side and “20” on the opposite side.

Otezla 30 mg film-coated tablets

Beige, diamond shaped 30 mg film-coated tablet of 12 mm length with “APR” engraved on one side and “30” on the opposite side.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Psoriatic arthritis</u></p><p>Otezla, alone or in combination with Disease Modifying Antirheumatic Drugs (DMARDs), is indicated for the treatment of active psoriatic arthritis (PsA) in adult patients who have had an inadequate response or who have been intolerant to a prior DMARD therapy (see section 5.1).</p><p>&nbsp;</p><p><u>Psoriasis</u></p><p>Otezla is indicated for the treatment of moderate to severe chronic plaque psoriasis in adult patients who failed to respond to or who have a contraindication to, or are intolerant to other systemic therapy including cyclosporine, methotrexate or psoralen and ultraviolet-A light (PUVA).</p><p>&nbsp;</p><p><u>Beh&ccedil;et&rsquo;s disease</u></p><p>Otezla is indicated for the treatment of adult patients with oral ulcers associated with Beh&ccedil;et&rsquo;s disease (BD) who are candidates for systemic therapy.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Treatment with Otezla should be initiated by specialists experienced in the diagnosis and treatment of psoriasis, psoriatic arthritis or Beh&ccedil;et&rsquo;s disease.</p><p>&nbsp;</p><p><u>Posology</u></p><p>The recommended dose of apremilast is 30&nbsp;mg taken orally twice daily, approximately 12 hours apart (morning and evening), with no food restrictions. An initial titration schedule is required as shown below in table 1. No re-titration is required after initial titration.</p><p>&nbsp;</p><p><strong>T</strong><strong>able 1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dose titration schedule</strong></p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p>Day 1</p></td><td colspan="2" style="vertical-align:top"><p>Day 2</p></td><td colspan="2" style="vertical-align:top"><p>Day 3</p></td><td colspan="2" style="vertical-align:top"><p>Day 4</p></td><td colspan="2" style="vertical-align:top"><p>Day 5</p></td><td colspan="2" style="vertical-align:top"><p>Day 6 &amp; thereafter</p></td></tr><tr><td style="vertical-align:top"><p>AM</p></td><td style="vertical-align:top"><p>AM</p></td><td style="vertical-align:top"><p>PM</p></td><td style="vertical-align:top"><p>AM</p></td><td style="vertical-align:top"><p>PM</p></td><td style="vertical-align:top"><p>AM</p></td><td style="vertical-align:top"><p>PM</p></td><td style="vertical-align:top"><p>AM</p></td><td style="vertical-align:top"><p>PM</p></td><td style="vertical-align:top"><p>AM</p></td><td style="vertical-align:top"><p>PM</p></td></tr><tr><td style="vertical-align:top"><p>10&nbsp;mg</p></td><td style="vertical-align:top"><p>10&nbsp;mg</p></td><td style="vertical-align:top"><p>10&nbsp;mg</p></td><td style="vertical-align:top"><p>10&nbsp;mg</p></td><td style="vertical-align:top"><p>20&nbsp;mg</p></td><td style="vertical-align:top"><p>20&nbsp;mg</p></td><td style="vertical-align:top"><p>20&nbsp;mg</p></td><td style="vertical-align:top"><p>20&nbsp;mg</p></td><td style="vertical-align:top"><p>30&nbsp;mg</p></td><td style="vertical-align:top"><p>30&nbsp;mg</p></td><td style="vertical-align:top"><p>30&nbsp;mg</p></td></tr></tbody></table><p>&nbsp;</p><p>If patients miss a dose, the next dose should be taken as soon as possible. If it is close to the time for their next dose, the missed dose should not be taken and the next dose should be taken at the regular time.</p><p>&nbsp;</p><p>During pivotal trials the greatest improvement was observed within the first 24 weeks of treatment for PsA and PSOR and within the first 12 weeks of treatment for BD. If a patient shows no evidence of therapeutic benefit after this time period, treatment should be reconsidered. The patient&#39;s response to treatment should be evaluated on a regular basis.</p><p>&nbsp;</p><p><u>Special populations</u></p><p><em><u>&nbsp;</u></em></p><p><em><u>Elderly patients</u></em></p><p>No dose adjustment is required for this patient population (see sections 4.8 and 5.2).</p><p>&nbsp;</p><p><em><u>Patients with renal impairment</u></em></p><p>No dose adjustment is needed in patients with mild and moderate renal impairment. The dose of apremilast should be reduced to 30&nbsp;mg once daily in patients with severe renal impairment (creatinine clearance of less than 30&nbsp;mL per minute estimated by the Cockcroft-Gault equation). For initial dose titration in this group, it is recommended that apremilast be titrated using only the AM schedule listed in table 1 and the PM doses be skipped (see section 5.2).</p><p>&nbsp;</p><p><em><u>Patients with hepatic impairment</u></em></p><p>No dose adjustment is necessary for patients with hepatic impairment (see section 5.2).</p><p>&nbsp;</p><p><em><u>Paediatric population</u></em></p><p>The safety and efficacy of apremilast in children aged 0 to 17 years have not been established. No data are available.</p><p>&nbsp;</p><p><u>Method of administration</u></p><p>&nbsp;</p><p>Otezla is for oral use. The film-coated tablets should be swallowed whole, and can be taken either with or without food.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance(s) or to any of the excipients listed in section 6.1.



Pregnancy (see section 4.6).
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>D</u><u>i</u><u>arrhoea, nausea, and vomiting</u></p><p>There have been post-marketing reports of severe diarrhoea, nausea, and vomiting associated with the use of apremilast. Most events occurred within the first few weeks of treatment. In some cases, patients were hospitalised. Patients 65 years of age or older may be at a higher risk of complications. If patients develop severe diarrhoea, nausea, or vomiting, discontinuation of treatment with apremilast may be necessary<em>.</em></p><p>&nbsp;</p><p><u>Psychiatric disorders</u></p><p>Apremilast is associated with an increased risk of psychiatric disorders such as insomnia and depression. Instances of suicidal ideation and behaviour, including suicide, have been observed in patients with or without history of depression (see section 4.8). The risks and benefits of starting or continuing treatment with apremilast should be carefully assessed if patients report previous or existing psychiatric symptoms or if concomitant treatment with other medicinal products likely to cause psychiatric events is intended. Patients and caregivers should be instructed to notify the prescriber of any changes in behaviour or mood and of any suicidal ideation. If patients suffered from new or worsening psychiatric symptoms, or suicidal ideation or suicidal attempt is identified, it is recommended to discontinue treatment with apremilast<em>.</em></p><p>&nbsp;</p><p><u>Severe renal impairment</u></p><p>Otezla should be dose reduced to 30&nbsp;mg once daily in patients with severe renal impairment (see sections 4.2 and 5.2).</p><p>&nbsp;</p><p><u>U</u><u>nderweight patients</u></p><p>Patients who are underweight at the start of treatment should have their body weight monitored regularly. In the event of unexplained and clinically significant weight loss, these patients should be evaluated by a medical practitioner and discontinuation of treatment should be considered.</p><p><u>&nbsp;</u></p><p><u>Lactose content</u></p><p>Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption should not take this medicinal product.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&nbsp;</p><p>Co-administration of strong cytochrome P450 3A4 (CYP3A4) enzyme inducer, rifampicin, resulted in a reduction of systemic exposure of apremilast, which may result in a loss of efficacy of apremilast. Therefore, the use of strong CYP3A4 enzyme inducers (e.g. rifampicin, phenobarbital, carbamazepine, phenytoin and St. John&rsquo;s Wort) with apremilast is not recommended. Co-administration of apremilast with multiple doses of rifampicin resulted in a decrease in apremilast area-under-the-concentration time curve (AUC) and maximum serum concentration (C<sub>max</sub>) by approximately 72% and 43%, respectively. Apremilast exposure is decreased when administered concomitantly with strong inducers of CYP3A4 (e.g. rifampicin) and may result in reduced clinical response.</p><p>&nbsp;</p><p>In clinical studies, apremilast has been administered concomitantly with topical therapy (including corticosteroids, coal tar shampoo and salicylic acid scalp preparations) and UVB phototherapy.</p><p>&nbsp;</p><p>There was no clinically meaningful interaction between ketoconazole and apremilast. Apremilast can be co‑administered with a potent CYP3A4 inhibitor such as ketoconazole.</p><p>&nbsp;</p><p>There was no pharmacokinetic interaction between apremilast and methotrexate in psoriatic arthritis patients. Apremilast can be co-administered with methotrexate.</p><p>&nbsp;</p><p>There was no pharmacokinetic interaction between apremilast and oral contraceptives containing ethinyl estradiol and norgestimate. Apremilast can be co-administered with oral contraceptives.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Women of childbearing potential</u></p><p>Pregnancy should be excluded before treatment can be initiated. Women of childbearing potential should use an effective method of contraception to prevent pregnancy during treatment.</p><p>&nbsp;</p><p><u>Pregnancy</u></p><p>There are limited data about the use of apremilast in pregnant women.</p><p>&nbsp;</p><p>Apremilast is contraindicated during pregnancy (see section 4.3). Effects of apremilast on pregnancy included embryo-foetal loss in mice and monkeys, and reduced foetal weights and delayed ossification in mice at doses higher than the currently recommended highest human dose. No such effects were observed when exposure in animals was at 1.3-fold the clinical exposure (see section 5.3).</p><p>&nbsp;</p><p><u>Lactation</u></p><p>Apremilast was detected in milk of lactating mice (see section 5.3). It is not known whether apremilast, or its metabolites, are excreted in human milk. A risk to the breastfed infant cannot be excluded, therefore apremilast should not be used during breast-feeding.</p><p>&nbsp;</p><p><u>Fertility</u></p><p>No fertility data is available in humans. In animal studies in mice, no adverse effects on fertility were observed in males at exposure levels 3-fold clinical exposure and in females at exposure levels 1-fold clinical exposure. For pre-clinical fertility data, see section 5.3.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Apremilast has no or negligible influence on the ability to drive and use machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary of the safety profile</u></p><p>The most commonly reported adverse reactions with apremilast in PsA and PSOR are gastrointestinal (GI) disorders including diarrhoea (15.7%) and nausea (13.9%). The other most commonly reported adverse reactions include upper respiratory tract infections (8.4%), headache (7.9%), and tension headache (7.2%) and are mostly mild to moderate in severity.</p><p>&nbsp;</p><p>The most commonly reported adverse drug reactions with apremilast in BD are diarrhoea (41.3%), nausea (19.2%), headache (14.4%), upper respiratory tract infection (11.5%), upper abdominal pain (8.7%), vomiting (8.7%) and back pain (7.7%) and are mostly mild to moderate in severity.</p><p>&nbsp;</p><p>The gastrointestinal adverse reactions generally occurred within the first 2&nbsp;weeks of treatment and usually resolved within 4&nbsp;weeks.</p><p>&nbsp;</p><p>Hypersensitivity reactions are uncommonly observed (see section 4.3).</p><p>&nbsp;</p><p><u>T</u><u>abulated list of adverse reactions</u></p><p>The adverse reactions observed in patients treated with apremilast are listed below by system organ class (SOC) and frequency for all adverse reactions. Within each SOC and frequency grouping, adverse reactions are presented in order of decreasing seriousness.</p><p>&nbsp;</p><p>The adverse drug reactions were determined based on data from the apremilast clinical development programme and post-marketing experience. The frequencies of adverse drug reactions are those reported in the apremilast arms of the four Phase III studies in PsA (n = 1,945) or the two Phase III studies in PSOR (n=1,184), and in the Phase III study in BD (n&nbsp;=&nbsp;207) the (highest frequency from either data pool is represented in table 2).</p><p>&nbsp;</p><p>Frequencies are defined as: very common (&ge;&nbsp;1/10); common (&ge;&nbsp;1/100 to &lt;&nbsp;1/10); uncommon (&ge;&nbsp;1/1,000 to &lt;&nbsp;1/100); rare (&ge;&nbsp;1/10,000 to &lt;&nbsp;1/1,000); not known (cannot be estimated from the available data).</p><p>&nbsp;</p><p><strong>T</strong><strong>able 2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Summary of adverse reactions in psoriatic arthritis (PsA), psoriasis (PSOR) </strong><strong>and Beh&ccedil;et&rsquo;s disease (BD)</strong></p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:98%"><thead><tr><td style="vertical-align:top"><p><strong>System Organ Class</strong></p></td><td style="vertical-align:top"><p><strong>F</strong><strong>r</strong><strong>equency</strong></p></td><td style="vertical-align:top"><p><strong>A</strong><strong>dverse reaction</strong></p></td></tr></thead><tbody><tr><td rowspan="4" style="vertical-align:top"><p>Infections and infestations</p></td><td><p>Very common</p></td><td><p>Upper respiratory tract infection<sup>a</sup></p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Bronchitis</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Nasopharyngitis*</p></td></tr><tr><td><p>Immune system disorders</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Hypersensitivity</p></td></tr><tr><td style="vertical-align:top"><p>Metabolism and nutrition disorders</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Decreased appetite*</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>Psychiatric disorders</p></td><td rowspan="2" style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Insomnia</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Depression</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Suicidal ideation and behaviour</p></td></tr><tr><td rowspan="4" style="vertical-align:top"><p>Nervous system disorders</p></td><td><p>Very common</p></td><td><p>Headache*<sup>, a</sup></p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Migraine*</p></td></tr><tr><td style="vertical-align:top"><p>Tension headache*</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Respiratory, thoracic, and mediastinal disorders</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Cough</p></td></tr><tr><td rowspan="8" style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td rowspan="2" style="vertical-align:top"><p>Very Common</p></td><td style="vertical-align:top"><p>Diarrhoea*</p></td></tr><tr><td style="vertical-align:top"><p>Nausea*</p></td></tr><tr><td rowspan="5" style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Vomiting*</p></td></tr><tr><td style="vertical-align:top"><p>Dyspepsia</p></td></tr><tr><td style="vertical-align:top"><p>Frequent bowel movements</p></td></tr><tr><td style="vertical-align:top"><p>Upper abdominal pain *</p></td></tr><tr><td style="vertical-align:top"><p>Gastroesophageal reflux disease</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Gastrointestinal haemorrhage</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>Skin and subcutaneous tissue disorders</p></td><td rowspan="2" style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Rash</p></td></tr><tr><td style="vertical-align:top"><p>Urticaria</p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Angioedema</p></td></tr><tr><td style="vertical-align:top"><p>Musculoskeletal and connective tissue disorders</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Back pain*</p></td></tr><tr><td style="vertical-align:top"><p>General disorders and administration site conditions</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Fatigue</p></td></tr><tr><td style="vertical-align:top"><p>Investigations</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Weight decrease</p></td></tr></tbody></table><p>*At least one of these adverse reactions was reported as serious</p><p><sup>a</sup> Frequency reported as common in PSA and PSOR</p><p>&nbsp;</p><p><u>D</u><u>escription of selected adverse reactions</u></p><p>&nbsp;</p><p><em><u>Psychiatric disorders</u></em></p><p>In clinical studies and post-marketing experience, uncommon cases of suicidal ideation and behaviour, were reported, while completed suicide was reported post-marketing. Patients and caregivers should be instructed to notify the prescriber of any suicidal ideation (see section 4.4).</p><p>&nbsp;</p><p><em><u>Body weight loss</u></em></p><p>Patient weight was measured routinely in clinical studies. The mean observed weight loss in PsA and PSOR patients treated for up to 52 weeks with apremilast was 1.99&nbsp;kg. A total of 14.3% of patients receiving apremilast had observed weight loss between 5-10% while 5.7% of the patients receiving apremilast had observed weight loss greater than 10%. None of these patients had overt clinical consequences resulting from weight loss. A total of 0.1% of patients treated with apremilast discontinued due to adverse reaction of weight decreased. The mean observed weight loss in BD patients treated with apremilast for 52 weeks was 0.52&nbsp;kg. A total of 11.8% of patients receiving apremilast had observed weight loss between 5-10% while 3.8% of the patients receiving apremilast had observed weight loss greater than 10%. None of these patients had overt clinical consequences from weight loss. None of the patients discontinued the study due to adverse reaction of weight decreased.</p><p>&nbsp;</p><p>Please see additional warning in section 4.4 for patients who are underweight at beginning of treatment.</p><p>&nbsp;</p><p><u>Special populations</u></p><p>&nbsp;</p><p><em><u>Elderly patients</u></em></p><p>From post-marketing experience, elderly patients &ge; 65 years of age may be at a higher risk of complications of severe diarrhoea, nausea and vomiting (see section 4.4).</p><p>&nbsp;</p><p><em><u>Patients with hepatic impairment</u></em></p><p>The safety of apremilast was not evaluated in PsA, PSOR or BD patients with hepatic impairment.</p><p>&nbsp;</p><p><em><u>Patients with renal impairment</u></em></p><p>In the PsA, PSOR or BD clinical studies, the safety profile observed in patients with mild renal impairment was comparable to patients with normal renal function. The safety of apremilast was not evaluated in PsA, PSOR or BD patients with moderate or severe renal impairment in the clinical studies.</p><p>&nbsp;</p><p><u>R</u><u>eporting of suspected adverse reactions</u></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions to their local representative.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:624px"><tbody><tr><td style="vertical-align:top"><p>To report any side effects:</p><p>Saudi Arabia:</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The National Pharmacovigilance Centre (NPC):</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SFDA Call Center: 19999</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Website: https://ade.sfda.gov.sa/</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Apremilast was studied in healthy subjects at a maximum total daily dose of 100&nbsp;mg (given as 50&nbsp;mg twice daily) for 4.5 days without evidence of dose limiting toxicities. In case of an overdose, it is recommended that the patient is monitored for any signs or symptoms of adverse effects and appropriate symptomatic treatment is instituted. In the event of overdose, symptomatic and supportive care is advised.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Immunosuppressants, selective immunosuppressants, ATC code: L04AA32</p><p>&nbsp;</p><p><u>Mechanism of action</u></p><p>Apremilast, an oral small-molecule inhibitor of phosphodiesterase 4 (PDE4), works intracellularly to modulate a network of pro-inflammatory and anti-inflammatory mediators. PDE4 is a cyclic adenosine monophosphate (cAMP)-specific PDE and the dominant PDE in inflammatory cells. PDE4 inhibition elevates intracellular cAMP levels, which in turn down-regulates the inflammatory response by modulating the expression of TNF‑&alpha;, IL-23, IL-17 and other inflammatory cytokines. Cyclic AMP also modulates levels of anti‑inflammatory cytokines such as IL-10. These pro- and anti-inflammatory mediators have been implicated in psoriatic arthritis and psoriasis.</p><p>&nbsp;</p><p><u>Pharmacodynamic effects</u></p><p>In clinical studies in patients with psoriatic arthritis, apremilast significantly modulated, but did not fully inhibit, plasma protein levels of IL-1&alpha;, IL-6, IL-8, MCP-1, MIP-1&beta;, MMP-3, and TNF-&alpha;. After 40 weeks of treatment with apremilast, there was a decrease in plasma protein levels of IL-17 and IL-23, and an increase in IL-10. In clinical studies in patients with psoriasis, apremilast decreased lesional skin epidermal thickness, inflammatory cell infiltration, and expression of pro-inflammatory genes, including those for inducible nitric oxide synthase (iNOS), IL-12/IL-23p40, IL-17A, IL-22 and IL-8. In clinical studies in patients with Beh&ccedil;et&rsquo;s disease treated with apremilast, there was a significant positive association between the change in plasma TNF-&alpha; and clinical efficacy as measured by the number of oral ulcers.</p><p>&nbsp;</p><p>Apremilast administered at doses of up to 50&nbsp;mg twice daily did not prolong the QT interval in healthy subjects.</p><p>&nbsp;</p><p><em><u>C</u></em><em><u>li</u></em><em><u>n</u></em><em><u>i</u></em><em><u>cal efficacy and safety </u></em></p><p>&nbsp;</p><p><em><u>Psoriatic Arthritis</u></em></p><p>The safety and efficacy of apremilast were evaluated in 3 multi-centre, randomised, double-blind, placebo-controlled studies (Studies PALACE 1, PALACE 2 and PALACE 3) of similar design in adult patients with active PsA (&ge; 3 swollen joints and &ge; 3 tender joints) despite prior treatment with small molecule or biologic DMARDs. A total of 1,493 patients were randomised and treated with either placebo, apremilast 20&nbsp;mg or apremilast 30&nbsp;mg given orally twice daily.</p><p>&nbsp;</p><p>Patients in these studies had a diagnosis of PsA for at least 6 months. One qualifying psoriatic skin lesion (at least 2&nbsp;cm in diameter) was also required in PALACE 3. Apremilast was used as a monotherapy (34.8%) or in combination with stable doses of small molecule DMARDs (65.2%). Patients received apremilast in combination with one or more of the following: methotrexate (MTX, &le; 25&nbsp;mg/week, 54.5%), sulfasalazine (SSZ, &le; 2&nbsp;g/day, 9.0%), and leflunomide (LEF; &le; 20&nbsp;mg/day, 7.4%). Concomitant treatment with biologic DMARDs, including TNF blockers, was not allowed. Patients with each subtype of PsA were enrolled in the 3 studies, including symmetric polyarthritis (62.0%), asymmetric oligoarthritis (26.9%), distal interphalangeal (DIP) joint arthritis (6.2%), arthritis mutilans (2.7%), and predominant spondylitis (2.1%). Patients with pre-existing enthesopathy (63%) or pre-existing dactylitis (42%) were enrolled. A total of 76.4% of patients were previously treated with only small-molecule DMARDs and 22.4% of patients were previously treated with biologic DMARDs, which includes 7.8% who had a therapeutic failure with a prior biologic DMARD. The median duration of PsA disease was 5 years.</p><p>&nbsp;</p><p>Based on the study design, patients whose tender and swollen joint counts had not improved by at least 20% were considered non-responders at week 16. Placebo patients who were considered non-responders were re‑randomised 1:1 in a blinded fashion to either apremilast 20&nbsp;mg twice daily or 30&nbsp;mg twice daily. At week 24, all remaining placebo-treated patients were switched to either apremilast 20 or 30&nbsp;mg twice daily. Following 52 weeks of treatment, patients could continue on open-label apremilast 20&nbsp;mg or 30&nbsp;mg within the long-term extension of the PALACE&nbsp;1, PALACE&nbsp;2 and PALACE&nbsp;3 studies for a total duration of treatment up to 5 years (260 weeks).</p><p>&nbsp;</p><p>The primary endpoint was the percentage of patients achieving American College of Rheumatology (ACR) 20 response at week 16.</p><p>&nbsp;</p><p>Treatment with apremilast resulted in significant improvements in the signs and symptoms of PsA, as assessed by the ACR 20 response criteria compared to placebo at weeks 16. The proportion of patients with ACR 20/50/70 (responses in studies PALACE 1, PALACE 2 and PALACE 3, and the pooled data for studies PALACE 1, PALACE 2 and PALACE 3), for apremilast 30&nbsp;mg twice daily at week 16 are shown in table 3. ACR 20/50/70 responses were maintained at week 24.</p><p>&nbsp;</p><p>Among patients who were initially randomised to apremilast 30&nbsp;mg twice daily treatment, ACR 20/50/70 response rates were maintained through week 52 in the pooled studies PALACE 1, PALACE 2 and PALACE 3 (figure 1).</p><p>&nbsp;</p><p><strong>T</strong><strong>able 3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Proportion of patients with ACR responses in studies PALACE 1, PALACE 2 and PALACE 3 and pooled studies at week 16</strong></p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:103%"><thead><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p><strong><u>PALACE 1</u></strong></p></td><td colspan="2" style="vertical-align:top"><p><strong><u>PALACE 2</u></strong></p></td><td colspan="2" style="vertical-align:top"><p><strong><u>PALACE 3</u></strong></p></td><td colspan="2" style="vertical-align:top"><p><strong><u>POOLED</u></strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p><strong><u>N</u></strong><strong><u><sup>a</sup></u></strong></p></td><td style="vertical-align:top"><p><strong><u>Placebo</u></strong></p><p>&nbsp;</p><p><strong><u>+</u></strong><strong><u>/-</u></strong><strong> <u>DMARDsN = 168</u></strong></p></td><td style="vertical-align:top"><p><strong><u>Apremilast</u></strong></p><p><strong><u>30</u></strong><strong><u>&nbsp;mg </u></strong><strong><u>twice daily</u></strong></p><p><strong><u>+</u></strong><strong><u>/-</u></strong><strong> <u>DMARDsN = 168</u></strong></p></td><td style="vertical-align:top"><p><strong><u>Placebo</u></strong></p><p>&nbsp;</p><p><strong><u>+</u></strong><strong><u>/-</u></strong><strong> <u>DMARDsN = 159</u></strong></p></td><td style="vertical-align:top"><p><strong><u>Apremilast</u></strong></p><p><strong><u>30</u></strong><strong><u>&nbsp;mg </u></strong><strong><u>twice daily</u></strong></p><p><strong><u>+</u></strong><strong><u>/-</u></strong><strong> <u>DMARDsN = 162</u></strong></p></td><td style="vertical-align:top"><p><strong><u>Placebo</u></strong></p><p>&nbsp;</p><p><strong><u>+</u></strong><strong><u>/-</u></strong><strong> <u>DMARDsN = 169</u></strong></p></td><td style="vertical-align:top"><p><strong><u>Apremilast</u></strong></p><p><strong><u>30</u></strong><strong><u>&nbsp;mg </u></strong><strong><u>twice daily</u></strong><strong><u> </u></strong></p><p><strong><u>+</u></strong><strong><u>/-</u></strong><strong> <u>DMARDsN = 167</u></strong></p></td><td style="vertical-align:top"><p><strong><u>Placebo</u></strong></p><p>&nbsp;</p><p><strong><u>+</u></strong><strong><u>/-</u></strong><strong> <u>DMARDsN = 496</u></strong></p></td><td style="vertical-align:top"><p><strong><u>Apremilast</u></strong></p><p><strong><u>30</u></strong><strong><u>&nbsp;mg </u></strong><strong><u>twice daily</u></strong></p><p><strong><u>+</u></strong><strong><u>/-</u></strong><strong> <u>DMARDsN = 497</u></strong></p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p><strong>ACR 20a</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Week 16</strong></p></td><td style="vertical-align:top"><p>19.0%</p></td><td style="vertical-align:top"><p>38.1%**</p></td><td style="vertical-align:top"><p>18.9%</p></td><td style="vertical-align:top"><p>32.1%*</p></td><td style="vertical-align:top"><p>18.3%</p></td><td style="vertical-align:top"><p>40.7%**</p></td><td style="vertical-align:top"><p>18.8%</p></td><td style="vertical-align:top"><p>37.0%**</p></td></tr><tr><td style="vertical-align:top"><p><strong>ACR 50</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Week 16</strong></p></td><td style="vertical-align:top"><p>6.0%</p></td><td style="vertical-align:top"><p>16.1%*</p></td><td style="vertical-align:top"><p>5.0%</p></td><td style="vertical-align:top"><p>10.5%</p></td><td style="vertical-align:top"><p>8.3%</p></td><td style="vertical-align:top"><p>15.0%</p></td><td style="vertical-align:top"><p>6.5%</p></td><td style="vertical-align:top"><p>13.9%**</p></td></tr><tr><td style="vertical-align:top"><p><strong>ACR 70</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Week 16</strong></p></td><td style="vertical-align:top"><p>1.2%</p></td><td style="vertical-align:top"><p>4.2%</p></td><td style="vertical-align:top"><p>0.6%</p></td><td style="vertical-align:top"><p>1.2%</p></td><td style="vertical-align:top"><p>2.4%</p></td><td style="vertical-align:top"><p>3.6%</p></td><td style="vertical-align:top"><p>1.4%</p></td><td style="vertical-align:top"><p>3.0%</p></td></tr></tbody></table><p>&nbsp;</p><p>*p &le; 0.01 for apremilast vs. placebo</p><p>**p &le; 0.001 for apremilast vs. placebo</p><p>a N is the number of patients as randomised and treated</p><p>Figure 1 &nbsp;&nbsp;&nbsp; Proportion of ACR 20/50/70 responders through Week 52 in the pooled analysis of studies PALACE 1, PALACE 2 and PALACE 3 (NRI*)</p><p><strong>&nbsp;</strong></p><p><img alt="" width="609" height="802" src="data:image/png;base64,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" /></p><table border="0" cellspacing="0" cellpadding="0" style="width:551px"><tbody><tr><td style="vertical-align:top"><p>ACR 20</p></td><td colspan="2" style="vertical-align:top"><p>184/497 (37.0)</p></td><td style="vertical-align:top"><p>196/497 (39.4)</p></td><td colspan="2" style="vertical-align:top"><p>222/497 (44.7)</p></td><td style="vertical-align:top"><p>209/497 (42.1)</p></td></tr><tr><td style="vertical-align:top"><p>ACR 50</p></td><td colspan="2" style="vertical-align:top"><p>69/497 (13.9)</p></td><td style="vertical-align:top"><p>93/497 (18.7)</p></td><td colspan="2" style="vertical-align:top"><p>102/497 (20.5)</p></td><td style="vertical-align:top"><p>90/497 (18.1)</p></td></tr><tr><td style="vertical-align:top"><p>ACR 70</p></td><td colspan="2" style="vertical-align:top"><p>15/497 ( 3.0)</p></td><td style="vertical-align:top"><p>33/497 ( 6.6)</p></td><td colspan="2" style="vertical-align:top"><p>44/497 ( 8.9)</p></td><td style="vertical-align:top"><p>38/497 ( 7.6)</p></td></tr><tr><td colspan="2"><p>&nbsp;</p></td><td colspan="3" style="vertical-align:top"><p>Endpoint <!--[if mso & !supportInlineShapes & supportFields]><span
  style='mso-element:field-begin;mso-field-lock:yes'></span><span
  style='mso-spacerun:yes'> </span>SHAPE <span
  style='mso-spacerun:yes'> </span>\* MERGEFORMAT <span style='mso-element:
  field-separator'></span><![endif]--><!--[if gte vml 1]><v:group id="Group_x0020_30348"
   o:spid="_x0000_s1039" style='width:18.95pt;height:3.3pt;
   mso-position-horizontal-relative:char;mso-position-vertical-relative:line'
   coordsize="240792,41910" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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">
   <v:shape id="Shape_x0020_1183" o:spid="_x0000_s1040" style='position:absolute;
    left:330;width:44628;height:41910;visibility:visible;mso-wrap-style:square;
    v-text-anchor:top' coordsize="44628,41910" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" path="m44628,21336r,-6096l41580,12192r,-3048l38532,6096r-3048,l35484,3048,29388,,17958,,11862,6096r-3048,l5766,9144r,3048l2718,15240r,9144c9881,28994,,26200,14910,38862r5334,l23292,41910r3048,-3048l35484,38862r,-3048l41580,29718r,-3048l44628,24384r,-3048e"
    filled="f" strokecolor="#007f00" strokeweight=".08256mm">
    <v:stroke endcap="round"/>
    <v:path arrowok="t" textboxrect="0,0,44628,41910"/>
   </v:shape><v:shape id="Shape_x0020_1184" o:spid="_x0000_s1041" style='position:absolute;
    left:98298;width:41148;height:41910;visibility:visible;mso-wrap-style:square;
    v-text-anchor:top' coordsize="41148,41910" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH
70i8Q+QralM4IITa7kDhCAiNB7ASt43WOlEcyvb2pNu4IODoPz9/n1xv9vOkForiPDdwXVagiI23
jocG3rdPxR0oScgWJ8/UwIEENu3lRb09BBKV0ywNjCmFe63FjDSjlD4Q50nv44wpl3HQAc0OB9I3
VXWrjedEnIq03oC27qjHjympx31un0wiTQLq4bS4shrAECZnMGVTvbD9QSnOhDInjzsyuiBXWQP0
r4R18jfgnHvJr4nOknrFmJ5xzhraRtHWf3Kkpfz/yGo5S+H73hkquyhdjr3R8m2lj09svwAAAP//
AwBQSwMEFAAGAAgAAAAhAFr0LFu/AAAAFQEAAAsAAABfcmVscy8ucmVsc2zPwWrDMAwG4Ptg72B0
X5TuUMaI01uh19I+gLGVxCy2jGSy9e1nemrHjpL4P0nD4SetZiPRyNnCruvBUPYcYp4tXC/Htw8w
Wl0ObuVMFm6kcBhfX4Yzra62kC6xqGlKVgtLreUTUf1CyWnHhXKbTCzJ1VbKjMX5LzcTvvf9HuXR
gPHJNKdgQU5hB+ZyK23zHztFL6w81c5zQp6m6P9TMfB3PtPWFCczVQtB9N4U2rp2HOA44NMz4y8A
AAD//wMAUEsDBBQABgAIAAAAIQA5Di5zwAAAAN0AAAAPAAAAZHJzL2Rvd25yZXYueG1sRE9La8JA
EL4X/A/LCN7qJlrURlcRQfDqA70O2WkS3J0N2VHTf98tFHqbj+85q03vnXpSF5vABvJxBoq4DLbh
ysDlvH9fgIqCbNEFJgPfFGGzHrytsLDhxUd6nqRSKYRjgQZqkbbQOpY1eYzj0BIn7it0HiXBrtK2
w1cK905PsmymPTacGmpsaVdTeT89vIFj7oKdzsVJuFT59mrj7fMQjRkN++0SlFAv/+I/98Gm+fni
A36/SSfo9Q8AAAD//wMAUEsBAi0AFAAGAAgAAAAhANvh9svuAAAAhQEAABMAAAAAAAAAAAAAAAAA
AAAAAFtDb250ZW50X1R5cGVzXS54bWxQSwECLQAUAAYACAAAACEAWvQsW78AAAAVAQAACwAAAAAA
AAAAAAAAAAAfAQAAX3JlbHMvLnJlbHNQSwECLQAUAAYACAAAACEAOQ4uc8AAAADdAAAADwAAAAAA
AAAAAAAAAAAHAgAAZHJzL2Rvd25yZXYueG1sUEsFBgAAAAADAAMAtwAAAPQCAAAAAA==
" path="m41148,21336r,-6096l38100,12192r,-3048l35814,6096,29718,,14478,,8382,6096r-2286,l3048,9144r,3048l,15240r,9144l3048,26670r,3048l6096,32766r2286,3048l11430,38862r6096,l20574,41910r6096,-3048l32766,38862r3048,-3048l35814,32766r2286,-3048l38100,26670r3048,-2286l41148,21336e"
    filled="f" strokecolor="#007f00" strokeweight=".08256mm">
    <v:stroke endcap="round"/>
    <v:path arrowok="t" textboxrect="0,0,41148,41910"/>
   </v:shape><v:shape id="Shape_x0020_1185" o:spid="_x0000_s1042" style='position:absolute;
    left:195834;width:38862;height:41910;visibility:visible;mso-wrap-style:square;
    v-text-anchor:top' coordsize="38862,41910" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" path="m38862,21336r,-9144l26670,,12192,,6096,6096r-3048,l,9144,,29718r9144,9144l15240,38862r6096,3048l23622,38862r6096,l32766,35814r,-3048l38862,26670r,-5334e"
    filled="f" strokecolor="#007f00" strokeweight=".08256mm">
    <v:stroke endcap="round"/>
    <v:path arrowok="t" textboxrect="0,0,38862,41910"/>
   </v:shape><v:shape id="Shape_x0020_33686" o:spid="_x0000_s1043" style='position:absolute;
    top:12192;width:240792;height:14478;visibility:visible;mso-wrap-style:square;
    v-text-anchor:top' coordsize="240792,14478" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" path="m,l240792,r,14478l,14478,,e" fillcolor="#007f00" strokecolor="#007f00"
    strokeweight=".08256mm">
    <v:stroke endcap="round"/>
    <v:path arrowok="t" textboxrect="0,0,240792,14478"/>
   </v:shape><w:wrap type="none"/>
   <w:anchorlock/>
  </v:group><![endif]--><img width="26" height="7" src="file:///C:/Users/ph-a-/AppData/Local/Temp/msohtmlclip1/01/clip_image005.gif" /><!--[if mso & !supportInlineShapes & supportFields]><v:shape
   id="_x0000_i1027" type="#_x0000_t75" style='width:18.95pt;height:3.3pt'>
   <v:imagedata croptop="-65520f" cropbottom="65520f"/>
  </v:shape><span style='mso-element:field-end'></span><![endif]-->&nbsp;ACR 20&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[if mso & !supportInlineShapes & supportFields]><span
  style='mso-element:field-begin;mso-field-lock:yes'></span> SHAPE <span
  style='mso-spacerun:yes'> </span>\* MERGEFORMAT <span style='mso-element:
  field-separator'></span><![endif]--><!--[if gte vml 1]><v:group id="Group_x0020_30349"
   o:spid="_x0000_s1033" style='width:18.95pt;height:3.3pt;
   mso-position-horizontal-relative:char;mso-position-vertical-relative:line'
   coordsize="240792,41910" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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">
   <v:shape id="Shape_x0020_1187" o:spid="_x0000_s1034" style='position:absolute;
    left:3048;width:41910;height:41910;visibility:visible;mso-wrap-style:square;
    v-text-anchor:top' coordsize="41910,41910" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" path="m41910,21336r,-9144l29718,,15240,,9144,6096r-3048,l3048,9144r,6096l,21336r3048,3048l3048,29718r9144,9144l18288,38862r3048,3048l26670,38862r6096,l35814,35814r,-3048l41910,26670r,-5334e"
    filled="f" strokecolor="#007f00" strokeweight=".08256mm">
    <v:stroke endcap="round"/>
    <v:path arrowok="t" textboxrect="0,0,41910,41910"/>
   </v:shape><v:shape id="Shape_x0020_1188" o:spid="_x0000_s1035" style='position:absolute;
    left:101346;width:38862;height:41910;visibility:visible;mso-wrap-style:square;
    v-text-anchor:top' coordsize="38862,41910" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" path="m38862,21336r,-9144l35814,9144r,-3048l32766,6096,26670,,11430,,9144,3048,6096,6096r-3048,l,9144,,29718r9144,9144l14478,38862r6096,3048l23622,38862r6096,l35814,32766r,-3048l38862,26670r,-5334e"
    filled="f" strokecolor="#007f00" strokeweight=".08256mm">
    <v:stroke endcap="round"/>
    <v:path arrowok="t" textboxrect="0,0,38862,41910"/>
   </v:shape><v:shape id="Shape_x0020_1189" o:spid="_x0000_s1036" style='position:absolute;
    left:196596;width:38100;height:41910;visibility:visible;mso-wrap-style:square;
    v-text-anchor:top' coordsize="38100,41910" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" path="m38100,21336r,-9144l35052,9144r,-3048l32004,6096,29718,3048,26670,,11430,,5334,6096r-3048,l2286,9144,,12192,,26670r2286,3048l2286,32766r6096,6096l14478,38862r6096,3048l23622,38862r6096,l32004,35814r3048,-3048l35052,29718r3048,-3048l38100,21336e"
    filled="f" strokecolor="#007f00" strokeweight=".08256mm">
    <v:stroke endcap="round"/>
    <v:path arrowok="t" textboxrect="0,0,38100,41910"/>
   </v:shape><v:shape id="Shape_x0020_33688" o:spid="_x0000_s1037" style='position:absolute;
    top:12192;width:110490;height:14478;visibility:visible;mso-wrap-style:square;
    v-text-anchor:top' coordsize="110490,14478" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" path="m,l110490,r,14478l,14478,,e" fillcolor="#007f00" strokecolor="#007f00"
    strokeweight=".08256mm">
    <v:stroke endcap="round"/>
    <v:path arrowok="t" textboxrect="0,0,110490,14478"/>
   </v:shape><v:shape id="Shape_x0020_33689" o:spid="_x0000_s1038" style='position:absolute;
    left:175260;top:12192;width:65532;height:14478;visibility:visible;
    mso-wrap-style:square;v-text-anchor:top' coordsize="65532,14478" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" path="m,l65532,r,14478l,14478,,e" fillcolor="#007f00" strokecolor="#007f00"
    strokeweight=".08256mm">
    <v:stroke endcap="round"/>
    <v:path arrowok="t" textboxrect="0,0,65532,14478"/>
   </v:shape><w:wrap type="none"/>
   <w:anchorlock/>
  </v:group><![endif]--><img width="27" height="7" src="file:///C:/Users/ph-a-/AppData/Local/Temp/msohtmlclip1/01/clip_image006.gif" /><!--[if mso & !supportInlineShapes & supportFields]><v:shape
   id="_x0000_i1026" type="#_x0000_t75" style='width:18.95pt;height:3.3pt'>
   <v:imagedata croptop="-65520f" cropbottom="65520f"/>
  </v:shape><span style='mso-element:field-end'></span><![endif]-->&nbsp;ACR 50&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[if mso & !supportInlineShapes & supportFields]><span
  style='mso-element:field-begin;mso-field-lock:yes'></span> SHAPE <span
  style='mso-spacerun:yes'> </span>\* MERGEFORMAT <span style='mso-element:
  field-separator'></span><![endif]--><!--[if gte vml 1]><v:group id="Group_x0020_30350"
   o:spid="_x0000_s1026" style='width:18.2pt;height:3.3pt;
   mso-position-horizontal-relative:char;mso-position-vertical-relative:line'
   coordsize="230886,41910" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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">
   <v:shape id="Shape_x0020_1192" o:spid="_x0000_s1027" style='position:absolute;
    left:2286;width:38862;height:41910;visibility:visible;mso-wrap-style:square;
    v-text-anchor:top' coordsize="38862,41910" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" path="m38862,21336r,-9144l35814,9144r,-3048l32766,6096,29718,3048,27432,,12192,,6096,6096r-3048,l,9144,,29718r9144,9144l15240,38862r6096,3048l24384,38862r5334,l35814,32766r,-3048l38862,26670r,-5334e"
    filled="f" strokecolor="#007f00" strokeweight=".08256mm">
    <v:stroke endcap="round"/>
    <v:path arrowok="t" textboxrect="0,0,38862,41910"/>
   </v:shape><v:shape id="Shape_x0020_1193" o:spid="_x0000_s1028" style='position:absolute;
    left:97536;width:38862;height:41910;visibility:visible;mso-wrap-style:square;
    v-text-anchor:top' coordsize="38862,41910" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" path="m38862,21336r,-9144l35814,9144r,-3048l32766,6096,26670,,12192,,6096,6096r-3048,l3048,9144,,12192,,26670r3048,3048l3048,32766r6096,6096l15240,38862r5334,3048l23622,38862r6096,l35814,32766r,-3048l38862,26670r,-5334e"
    filled="f" strokecolor="#007f00" strokeweight=".08256mm">
    <v:stroke endcap="round"/>
    <v:path arrowok="t" textboxrect="0,0,38862,41910"/>
   </v:shape><v:shape id="Shape_x0020_1194" o:spid="_x0000_s1029" style='position:absolute;
    left:192786;width:38100;height:41910;visibility:visible;mso-wrap-style:square;
    v-text-anchor:top' coordsize="38100,41910" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" path="m38100,21336r,-9144l35814,9144r,-3048l32766,6096,26670,,11430,,8382,3048,6096,6096r-3048,l3048,9144,,12192,,26670r3048,3048l3048,32766r3048,3048l8382,38862r6096,l20574,41910r3048,-3048l29718,38862r6096,-6096l35814,29718r2286,-3048l38100,21336e"
    filled="f" strokecolor="#007f00" strokeweight=".08256mm">
    <v:stroke endcap="round"/>
    <v:path arrowok="t" textboxrect="0,0,38100,41910"/>
   </v:shape><v:shape id="Shape_x0020_33692" o:spid="_x0000_s1030" style='position:absolute;
    top:12192;width:23622;height:14478;visibility:visible;mso-wrap-style:square;
    v-text-anchor:top' coordsize="23622,14478" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" path="m,l23622,r,14478l,14478,,e" fillcolor="#007f00" strokecolor="#007f00"
    strokeweight=".08256mm">
    <v:stroke endcap="round"/>
    <v:path arrowok="t" textboxrect="0,0,23622,14478"/>
   </v:shape><v:shape id="Shape_x0020_33693" o:spid="_x0000_s1031" style='position:absolute;
    left:88392;top:12192;width:24384;height:14478;visibility:visible;
    mso-wrap-style:square;v-text-anchor:top' coordsize="24384,14478" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH
70i8Q+QralM4IITa7kDhCAiNB7ASt43WOlEcyvb2pNu4IODoPz9/n1xv9vOkForiPDdwXVagiI23
jocG3rdPxR0oScgWJ8/UwIEENu3lRb09BBKV0ywNjCmFe63FjDSjlD4Q50nv44wpl3HQAc0OB9I3
VXWrjedEnIq03oC27qjHjympx31un0wiTQLq4bS4shrAECZnMGVTvbD9QSnOhDInjzsyuiBXWQP0
r4R18jfgnHvJr4nOknrFmJ5xzhraRtHWf3Kkpfz/yGo5S+H73hkquyhdjr3R8m2lj09svwAAAP//
AwBQSwMEFAAGAAgAAAAhAFr0LFu/AAAAFQEAAAsAAABfcmVscy8ucmVsc2zPwWrDMAwG4Ptg72B0
X5TuUMaI01uh19I+gLGVxCy2jGSy9e1nemrHjpL4P0nD4SetZiPRyNnCruvBUPYcYp4tXC/Htw8w
Wl0ObuVMFm6kcBhfX4Yzra62kC6xqGlKVgtLreUTUf1CyWnHhXKbTCzJ1VbKjMX5LzcTvvf9HuXR
gPHJNKdgQU5hB+ZyK23zHztFL6w81c5zQp6m6P9TMfB3PtPWFCczVQtB9N4U2rp2HOA44NMz4y8A
AAD//wMAUEsDBBQABgAIAAAAIQCgZyYmxwAAAN4AAAAPAAAAZHJzL2Rvd25yZXYueG1sRI9Ba8JA
FITvgv9heYK3utHQoKmraLFQ2oPGlp4f2WcSzL5Nd1dN/323UPA4zMw3zHLdm1ZcyfnGsoLpJAFB
XFrdcKXg8+PlYQ7CB2SNrWVS8EMe1qvhYIm5tjcu6HoMlYgQ9jkqqEPocil9WZNBP7EdcfRO1hkM
UbpKaoe3CDetnCVJJg02HBdq7Oi5pvJ8vBgFxfTRvVXd+f3wne62WWNp97UnpcajfvMEIlAf7uH/
9qtWkKbZIoW/O/EKyNUvAAAA//8DAFBLAQItABQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAAAAA
AAAAAAAAAAAAAABbQ29udGVudF9UeXBlc10ueG1sUEsBAi0AFAAGAAgAAAAhAFr0LFu/AAAAFQEA
AAsAAAAAAAAAAAAAAAAAHwEAAF9yZWxzLy5yZWxzUEsBAi0AFAAGAAgAAAAhAKBnJibHAAAA3gAA
AA8AAAAAAAAAAAAAAAAABwIAAGRycy9kb3ducmV2LnhtbFBLBQYAAAAAAwADALcAAAD7AgAAAAA=
" path="m,l24384,r,14478l,14478,,e" fillcolor="#007f00" strokecolor="#007f00"
    strokeweight=".08256mm">
    <v:stroke endcap="round"/>
    <v:path arrowok="t" textboxrect="0,0,24384,14478"/>
   </v:shape><v:shape id="Shape_x0020_33694" o:spid="_x0000_s1032" style='position:absolute;
    left:177546;top:12192;width:23622;height:14478;visibility:visible;
    mso-wrap-style:square;v-text-anchor:top' coordsize="23622,14478" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" path="m,l23622,r,14478l,14478,,e" fillcolor="#007f00" strokecolor="#007f00"
    strokeweight=".08256mm">
    <v:stroke endcap="round"/>
    <v:path arrowok="t" textboxrect="0,0,23622,14478"/>
   </v:shape><w:wrap type="none"/>
   <w:anchorlock/>
  </v:group><![endif]--><img width="26" height="7" src="file:///C:/Users/ph-a-/AppData/Local/Temp/msohtmlclip1/01/clip_image007.gif" /><!--[if mso & !supportInlineShapes & supportFields]><v:shape
   id="_x0000_i1025" type="#_x0000_t75" style='width:18.2pt;height:3.3pt'>
   <v:imagedata croptop="-65520f" cropbottom="65520f"/>
  </v:shape><span style='mso-element:field-end'></span><![endif]-->&nbsp;ACR 70</p></td><td colspan="2"><p>&nbsp;</p></td></tr><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr></tbody></table><p>&nbsp;</p><p>*NRI: None responder imputation. Subjects who discontinued early prior to the time point and subjects who did not have sufficient data for a definitive determination of response status at the time point are counted as non-responders.</p><p>&nbsp;</p><p>Among 497 patients initially randomised to apremilast 30&nbsp;mg twice daily, 375 (75%) patients were still on this treatment on week 52. In these patients, ACR 20/50/70 responses at week 52 were of 57%, 25%, and 11% respectively. Among 497 patients initially randomised to apremilast 30&nbsp;mg twice daily, 375 (75%) patients entered the long-term extension studies, and of these, 221 patients (59%) were still on this treatment at week 260. ACR responses were maintained in the long-term open-label extension studies for up to 5 years.</p><p>&nbsp;</p><p>Responses observed in the apremilast-treated group were similar in patients receiving and not receiving concomitant DMARDs, including MTX. Patients previously treated with DMARDs or biologics who received apremilast achieved a greater ACR 20 response at week 16 than patients receiving placebo.</p><p>&nbsp;</p><p>Similar ACR responses were observed in patients with different PsA subtypes, including DIP. The number of patients with arthritis mutilans and predominant spondylitis subtypes was too small to allow meaningful assessment.</p><p>&nbsp;</p><p>In PALACE 1, PALACE 2 and PALACE 3, improvements in Disease Activity Scale (DAS) 28 C-reactive protein (CRP) and in the proportion of patients achieving a modified PsA response criteria (PsARC) were greater in the apremilast group, compared to placebo at week 16 (nominal p-value p&nbsp;<u>&lt;</u>&nbsp;0.0004, p-value&nbsp;&le;&nbsp;0.0017, respectively). These improvements were maintained at week 24. Among patients who remained on the apremilast treatment to which they were randomised at study start, DAS28(CRP) score and PsARC response were maintained through week 52.</p><p>&nbsp;</p><p>At weeks 16 and 24 improvements in parameters of peripheral activity characteristic of psoriatic arthritis (e.g. number of swollen joints, number of painful/tender joints, dactylitis and enthesitis) and in the skin manifestations of psoriasis were seen in the apremilast-treated patients. Among patients who remained on the apremilast treatment to which they were randomised at study start, these improvements were maintained through week 52.</p><p>&nbsp;</p><p>The clinical responses were maintained in the same parameters of peripheral activity and in the skin manifestations of psoriasis in the open-label extension studies for up to 5 years of treatment.</p><p>&nbsp;</p><p><u>Physical function and health-related quality of life</u></p><p>&nbsp;</p><p>Apremilast-treated patients demonstrated statistically significant improvement in physical function, as assessed by the disability index of the health assessment questionnaire (HAQ-DI) change from baseline, compared to placebo at weeks 16 in PALACE 1, PALACE 2 and PALACE 3 and in the pooled studies. Improvement in HAQ-DI scores was maintained at week 24.</p><p>&nbsp;</p><p>Among patients who were initially randomised to apremilast 30&nbsp;mg twice daily treatment, the change from baseline in the HAQ-DI score at week 52 was -0.333 in the apremilast 30&nbsp;mg twice daily group in a pooled analysis of the open-label phase of studies PALACE 1, PALACE 2 and PALACE 3.</p><p>&nbsp;</p><p>In studies PALACE 1, PALACE 2 and PALACE 3, significant improvements were demonstrated in health-related quality of life, as measured by the changes from baseline in the physical functioning (PF) domain of the Short Form Health Survey version 2 (SF-36v2), and in the Functional Assessment of Chronic Illness Therapy &ndash; Fatigue (FACIT-fatigue) scores in patients treated with apremilast compared to placebo at weeks 16 and 24. Among patients who remained on the apremilast treatment, to which they were initially randomised at study start, improvement in physical function and FACIT- fatigue was maintained through week 52.</p><p>&nbsp;</p><p>Improved physical function as assessed by the HAQ-DI and the SF36v2PF domain, and the FACIT‑fatigue scores were maintained in the open-label extension studies for up to 5 years of treatment.</p><p>&nbsp;</p><p><em><u>Psoriasis</u></em></p><p>The safety and efficacy of apremilast were evaluated in two multi-centre, randomised, double-blind, placebo-controlled studies (Studies ESTEEM 1 and ESTEEM 2) which enrolled a total of 1,257 patients with moderate to severe plaque psoriasis who had a body surface area (BSA) involvement of &ge; 10%, Psoriasis Area and Severity Index (PASI) score &ge; 12, static Physician Global Assessment (sPGA) of &ge; 3 (moderate or severe), and who were candidates for phototherapy or systemic therapy.</p><p>&nbsp;</p><p>These studies had a similar design through week 32. In both studies, patients were randomised 2:1 to apremilast 30&nbsp;mg twice daily or placebo for 16 weeks (placebo-controlled phase) and from weeks 16-32, all patients received apremilast 30&nbsp;mg twice daily (maintenance phase). During the Randomised Treatment Withdrawal Phase (weeks 32-52), patients originally randomised to apremilast who achieved at least a 75% reduction in their PASI score (PASI-75) (ESTEEM 1) or a 50% reduction in their PASI score (PASI-50) (ESTEEM 2) were re-randomised at week 32 to either placebo or apremilast 30&nbsp;mg twice daily. Patients who were re-randomised to placebo and who lost PASI-75 response (ESTEEM 1) or lost 50% of the PASI improvement at week 32 compared to baseline (ESTEEM 2) were retreated with apremilast 30&nbsp;mg twice daily. Patients who did not achieve the designated PASI response by week 32, or who were initially randomised to placebo, remained on apremilast until week 52. The use of low potency topical corticosteroids on the face, axillae, and groin, coal tar shampoo and/or salicylic acid scalp preparations was permitted throughout the studies. In addition, at week 32, subjects who did not achieve a PASI-75 response in ESTEEM 1, or a PASI-50 response in ESTEEM 2, were permitted to use topical psoriasis therapies and/or phototherapy in addition to apremilast 30&nbsp;mg twice daily treatment.</p><p>&nbsp;</p><p>Following 52 weeks of treatment, patients could continue on open-label apremilast 30&nbsp;mg within the long‑term extension of the ESTEEM 1 and ESTEEM 2 studies for a total duration of treatment up to 5 years (260 weeks).</p><p>&nbsp;</p><p>In both studies, the primary endpoint was the proportion of patients who achieved PASI-75 at week 16. The major secondary endpoint was the proportion of patients who achieved a sPGA score of clear (0) or almost clear (1) at week 16.</p><p>&nbsp;</p><p>The mean baseline PASI score was 19.07 (median 16.80), and the proportion of patients with sPGA score of 3 (moderate) and 4 (severe) at baseline was 70.0% and 29.8%, respectively with a mean baseline BSA involvement of 25.19% (median 21.0%). Approximately 30% of all patients had received prior phototherapy and 54% had received prior conventional systemic and/or biologic therapy for the treatment of psoriasis (including treatment failures), with 37% receiving prior conventional systemic therapy and 30% receiving prior biologic therapy. Approximately one-third of patients had not received prior phototherapy, conventional systemic or biologic therapy. A total of 18% of patients had a history of psoriatic arthritis.</p><p>&nbsp;</p><p>The proportion of patients achieving PASI-50, -75 and -90 responses, and sPGA score of clear (0) or almost clear (1), are presented in table 4 below. Treatment with apremilast resulted in significant improvement in moderate to severe plaque psoriasis as demonstrated by the proportion of patients with PASI-75 response at week 16, compared to placebo. Clinical improvement measured by sPGA, PASI-50 and PASI-90 responses were also demonstrated at week 16. In addition, apremilast demonstrated a treatment benefit across multiple manifestations of psoriasis including pruritus, nail disease, scalp involvement and quality of life measures.</p><p><strong>T</strong><strong>able 4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Clinical response at week 16 in studies ESTEEM 1 and ESTEEM 2 (FAS </strong><strong>a</strong><strong>, LOCF</strong><strong>b</strong><strong>)</strong></p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p><strong><u>E</u></strong><strong><u>STEEM 1</u></strong></p></td><td colspan="2" style="vertical-align:top"><p><strong><u>E</u></strong><strong><u>STEEM 2</u></strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong><u>Placebo</u></strong></p></td><td style="vertical-align:top"><p><strong><u>30&nbsp;mg </u></strong><strong><u>twice daily</u></strong><strong><u> </u></strong><strong><u>A</u></strong><strong><u>P</u></strong><strong><u>R</u></strong><strong><u>*</u></strong></p></td><td style="vertical-align:top"><p><strong><u>Placebo</u></strong></p></td><td style="vertical-align:top"><p><strong><u>30&nbsp;mg </u></strong><strong><u>twice daily </u></strong><strong><u>A</u></strong><strong><u>P</u></strong><strong><u>R</u></strong><strong><u>*</u></strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>N</strong></p></td><td style="vertical-align:top"><p>282</p></td><td style="vertical-align:top"><p>562</p></td><td style="vertical-align:top"><p>137</p></td><td style="vertical-align:top"><p>274</p></td></tr><tr><td style="vertical-align:top"><p><strong>P</strong><strong>A</strong><strong>SI</strong><strong>c </strong><strong>7</strong><strong>5, n (%)</strong></p></td><td style="vertical-align:top"><p>15 (5.3)</p></td><td style="vertical-align:top"><p>186 (33.1)</p></td><td style="vertical-align:top"><p>8 (5.8)</p></td><td style="vertical-align:top"><p>79 (28.8)</p></td></tr><tr><td style="vertical-align:top"><p><strong>sPGA</strong><strong>d </strong><strong>o</strong><strong>f clear or</strong></p><p><strong>a</strong><strong>lm</strong><strong>ost clear, n (%)</strong></p></td><td style="vertical-align:top"><p>11 (3.9)</p></td><td style="vertical-align:top"><p>122 (21.7)</p></td><td style="vertical-align:top"><p>6 (4.4)</p></td><td style="vertical-align:top"><p>56 (20.4)</p></td></tr><tr><td style="vertical-align:top"><p><strong>P</strong><strong>A</strong><strong>SI 50, n (%)</strong></p></td><td style="vertical-align:top"><p>48 (17.0)</p></td><td style="vertical-align:top"><p>330 (58.7)</p></td><td style="vertical-align:top"><p>27 (19.7)</p></td><td style="vertical-align:top"><p>152 (55.5)</p></td></tr><tr><td style="vertical-align:top"><p><strong>P</strong><strong>A</strong><strong>SI 90, n (%)</strong></p></td><td style="vertical-align:top"><p>1 (0.4)</p></td><td style="vertical-align:top"><p>55 (9.8)</p></td><td style="vertical-align:top"><p>2 (1.5)</p></td><td style="vertical-align:top"><p>24 (8.8)</p></td></tr><tr><td style="vertical-align:top"><p><strong>P</strong><strong>e</strong><strong>rcent change BSA</strong><strong>e </strong><strong>(</strong><strong>%</strong><strong>)</strong></p><p><strong>m</strong><strong>ean&plusmn; SD</strong></p></td><td style="vertical-align:top"><p>- 6.9</p><p>&plusmn; 38.95</p></td><td style="vertical-align:top"><p>- 47.8</p><p>&plusmn; 38.48</p></td><td style="vertical-align:top"><p>- 6.1</p><p>&plusmn; 47.57</p></td><td style="vertical-align:top"><p>-48.4</p><p>&plusmn; 40.78</p></td></tr><tr><td style="vertical-align:top"><p><strong>C</strong><strong>hange in pruritus VAS</strong><strong>f</strong></p><p><strong>(</strong><strong>m</strong><strong>m)</strong><strong>, mean&plusmn; SD</strong></p></td><td style="vertical-align:top"><p>- 7.3</p><p>&plusmn; 27.08</p></td><td style="vertical-align:top"><p>- 31.5</p><p>&plusmn; 32.43</p></td><td style="vertical-align:top"><p>- 12.2</p><p>&plusmn; 30.94</p></td><td style="vertical-align:top"><p>- 33.5</p><p>&plusmn;35.46</p></td></tr><tr><td style="vertical-align:top"><p><strong>C</strong><strong>hange in DLQI</strong><strong>g</strong><strong>, mean</strong>&plusmn;</p><p><strong>SD</strong></p></td><td style="vertical-align:top"><p>- 2.1</p><p>&plusmn; 5.69</p></td><td style="vertical-align:top"><p>- 6.6</p><p>&plusmn; 6.66</p></td><td style="vertical-align:top"><p>-2.8</p><p>&plusmn; 7.22</p></td><td style="vertical-align:top"><p>-6.7</p><p>&plusmn; 6.95</p></td></tr><tr><td style="vertical-align:top"><p><strong>C</strong><strong>hange in SF-36 MCS </strong><strong>h</strong><strong>, mean&plusmn; SD</strong></p></td><td style="vertical-align:top"><p>- 1.02</p><p>&plusmn; 9.161</p></td><td style="vertical-align:top"><p>2.39</p><p>&plusmn; 9.504</p></td><td style="vertical-align:top"><p>0.00</p><p>&plusmn;10.498</p></td><td style="vertical-align:top"><p>2.58</p><p>&plusmn; 10.129</p></td></tr></tbody></table><p>* p &lt; 0.0001 for apremilast vs. placebo, except for ESTEEM 2 PASI 90 and Change in SF-36 MCS where p=0.0042 and p=0.0078, respectively.</p><p>a FAS = Full Analysis Set</p><p>b LOCF= Last Observation Carried Forward</p><p>c PASI = Psoriasis Area and Severity Index</p><p>d sPGA = Static Physician Global Assessment</p><p>e BSA = Body Surface Area</p><p>f VAS = Visual Analog Scale; 0 = best, 100 = worst</p><p>g DLQI = Dermatology Life Quality Index; 0 = best, 30 = worst</p><p>h SF-36 MCS = Medical Outcome Study Short Form 36-Item Health Survey, Mental Component Summary</p><p>&nbsp;</p><p>The clinical benefit of apremilast was demonstrated across multiple subgroups defined by baseline demographics and baseline clinical disease characteristics (including psoriasis disease duration and patients with a history of psoriatic arthritis). The clinical benefit of apremilast was also demonstrated regardless of prior psoriasis medication usage and response to prior psoriasis treatments. Similar response rates were observed across all weight ranges.</p><p>&nbsp;</p><p>Response to apremilast was rapid, with significantly greater improvements in the signs and symptoms of psoriasis, including PASI, skin discomfort/pain and pruritus, compared to placebo by week 2. In general, PASI responses were achieved by week 16 and were maintained through week 32.</p><p>&nbsp;</p><p>In both studies, the mean percent improvement in PASI from baseline remained stable during the randomised treatment withdrawal phase for patients re-randomised to apremilast at week 32 (table 5).</p><p>&nbsp;</p><p><strong>T</strong><strong>able 5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Persistence of effect among subjects randomised to APR 30 </strong><strong>twice daily</strong><strong> </strong><strong>a</strong><strong>t week 0 and re-randomised to APR 30 </strong><strong>twice daily </strong><strong>at week 32 to week 52</strong></p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td rowspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td rowspan="2" style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p><strong><u>T</u></strong><strong><u>i</u></strong><strong><u>m</u></strong><strong><u>e Point</u></strong></p></td><td style="vertical-align:top"><p>&nbsp;</p><p><strong><u>E</u></strong><strong><u>S</u></strong><strong><u>T</u></strong><strong><u>E</u></strong><strong><u>E</u></strong><strong><u>M 1</u></strong></p></td><td style="vertical-align:top"><p>&nbsp;</p><p><strong><u>E</u></strong><strong><u>S</u></strong><strong><u>T</u></strong><strong><u>E</u></strong><strong><u>E</u></strong><strong><u>M 2</u></strong></p></td></tr><tr><td style="vertical-align:top"><p><strong><u>Patients who achieved PASI-75</u></strong><strong> <u>a</u></strong><strong><u>t week 32</u></strong></p></td><td style="vertical-align:top"><p><strong><u>Patients who achieved</u></strong></p><p><strong><u>PASI-50 at week 32</u></strong></p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p><strong>Percent Change in PASI from baseline, mean (%) &plusmn; SD</strong><strong>a</strong></p></td><td style="vertical-align:top"><p>Week 16</p></td><td style="vertical-align:top"><p>-77.7 &plusmn; 20.30</p></td><td style="vertical-align:top"><p>-69.7 &plusmn; 24.23</p></td></tr><tr><td style="vertical-align:top"><p>Week 32</p></td><td style="vertical-align:top"><p>-88 &plusmn; 8.30</p></td><td style="vertical-align:top"><p>-76.7 &plusmn; 13.42</p></td></tr><tr><td style="vertical-align:top"><p>Week 52</p></td><td style="vertical-align:top"><p>-80.5 &plusmn; 12.60</p></td><td style="vertical-align:top"><p>-74.4 &plusmn; 18.91</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>&nbsp;</p><p><strong>Change in DLQI from baseline, mean </strong>&plusmn; <strong>SD</strong><strong>a</strong></p></td><td style="vertical-align:top"><p>Week 16</p></td><td style="vertical-align:top"><p>-8.3 &plusmn; 6.26</p></td><td style="vertical-align:top"><p>-7.8 &plusmn; 6.41</p></td></tr><tr><td style="vertical-align:top"><p>Week 32</p></td><td style="vertical-align:top"><p>-8.9 &plusmn; 6.68</p></td><td style="vertical-align:top"><p>-7.7 &plusmn; 5.92</p></td></tr><tr><td style="vertical-align:top"><p>Week 52</p></td><td style="vertical-align:top"><p>-7.8 &plusmn; 5.75</p></td><td style="vertical-align:top"><p>-7.5 &plusmn; 6.27</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p><strong>Proportion of subjects with Scalp Psoriasis PGA (ScPGA) 0 or 1, n/N (%)</strong><strong>b</strong></p></td><td style="vertical-align:top"><p>Week 16</p></td><td style="vertical-align:top"><p>40/48 (83.3)</p></td><td style="vertical-align:top"><p>21/37 (56.8)</p></td></tr><tr><td style="vertical-align:top"><p>Week 32</p></td><td style="vertical-align:top"><p>39/48 (81.3)</p></td><td style="vertical-align:top"><p>27/37 (73.0)</p></td></tr><tr><td style="vertical-align:top"><p>Week 52</p></td><td style="vertical-align:top"><p>35/48 (72.9)</p></td><td style="vertical-align:top"><p>20/37 (54.1)</p></td></tr></tbody></table><p>a Includes subjects re-randomised to APR 30 twice daily&nbsp;at week 32 with a baseline value and a post-baseline value at the evaluated study week.</p><p>b N is based on subjects with moderate or greater scalp psoriasis at baseline who were re-randomised to APR 30 twice daily&nbsp;at week 32. Subjects with missing data were counted as non-responders.</p><p>&nbsp;</p><p>In study ESTEEM 1, approximately 61% of patients re-randomised to apremilast at week 32 had a PASI-75 response at week 52. Of the patients with at least a PASI-75 response who were re-randomised to placebo at week 32 during a randomised treatment withdrawal phase, 11.7% were PASI-75 responders at week 52. The median time to loss of PASI-75 response among the patients re-randomised to placebo was 5.1 weeks.</p><p>&nbsp;</p><p>In study ESTEEM 2, approximately 80.3% of patients re-randomised to apremilast at week 32 had a PASI-50 response at week 52. Of the patients with at least a PASI-50 response who were re-randomised to placebo at week 32, 24.2% were PASI-50 responders at week 52. The median time to loss of 50% of their week 32 PASI improvement was 12.4 weeks.</p><p>&nbsp;</p><p>After randomised withdrawal from therapy at week 32, approximately 70% of patients in study ESTEEM 1, and 65.6% of patients in study ESTEEM 2, regained PASI-75 (ESTEEM 1) or PASI-50 (ESTEEM 2) responses after re-initiation of apremilast treatment. Due to the study design the duration of re-treatment was variable, and ranged from 2.6 to 22.1 weeks.</p><p>&nbsp;</p><p>In study ESTEEM 1, patients randomised to apremilast at the start of the study who did not achieve a PASI-75 response at week 32 were permitted to use concomitant topical therapies and/or UVB phototherapy between weeks 32 to 52. Of these patients, 12% achieved a PASI-75 response at week 52 with apremilast plus topical and/or phototherapy treatment.</p><p>&nbsp;</p><p>In studies ESTEEM 1 and ESTEEM 2, significant improvements (reductions) in nail psoriasis, as measured by the mean percent change in Nail Psoriasis Severity Index (NAPSI) from baseline, were observed in patients receiving apremilast compared to placebo-treated patients at week 16 (p &lt; 0.0001 and p&nbsp;=&nbsp;0.0052, respectively). Further improvements in nail psoriasis were observed at week 32 in patients continuously treated with apremilast.</p><p>&nbsp;</p><p>In studies ESTEEM 1 and ESTEEM 2, significant improvements in scalp psoriasis of at least moderate severity (&ge; 3), measured by the proportion of patients achieving Scalp Psoriasis Physician&rsquo;s Global Assessment (ScPGA) of clear (0) or minimal (1) at week 16, were observed in patients receiving apremilast compared to placebo-treated patients (p &lt; 0.0001 for both studies). The improvements were generally maintained in subjects who were re-randomised to apremilast at week 32 through week 52 (table 5).</p><p>&nbsp;</p><p>In studies ESTEEM 1 and ESTEEM 2, significant improvements in quality of life as measured by the Dermatology Life Quality Index (DLQI) and the SF-36v2MCS were demonstrated in patients receiving apremilast compared with placebo-treated patients (table 4). Improvements in DLQI were maintained through week 52 in subjects who were re-randomised to apremilast at week 32 (table 5). In addition, in study ESTEEM 1, significant improvement in the Work Limitations Questionnaire (WLQ-25) Index was achieved in patients receiving apremilast compared to placebo.</p><p>&nbsp;</p><p>Among 832 patients initially randomised to apremilast 30&nbsp;mg twice daily, 443 patients (53%) entered the open-label extension studies of ESTEEM 1 and ESTEEM 2, and of these 115 patients (26%) were still on treatment at week 260. For patients who remained on apremilast in the open-label extension of ESTEEM 1 and ESTEEM 2 studies, improvements were generally maintained in PASI score, affected BSA, itch, nail and quality of life measures for up to 5 years.</p><p>&nbsp;</p><p>The long-term safety of apremilast 30&nbsp;mg twice daily in patients with psoriatic arthritis and psoriasis was assessed for a total duration of treatment up to 5 years. Long-term experience in open-label extension studies with apremilast was generally comparable to the 52-week studies.</p><p><u>&nbsp;</u></p><p><em><u>Beh&ccedil;et&rsquo;s disease</u></em></p><p>The safety and efficacy of apremilast were evaluated in a Phase III, multi-centre, randomised, placebo-controlled study (RELIEF) in adult patients with active Beh&ccedil;et&rsquo;s Disease (BD) with oral ulcers. Patients were previously treated with at least one non-biologic BD medication for oral ulcers and were candidates for systemic therapy. Concomitant treatment for BD was not allowed. The population studied met the International Study Group (ISG) criteria for BD with a history of skin lesions (98.6%), genital ulcers (90.3%), musculoskeletal (72.5%), ocular (17.4%), central nervous system (9.7%) or GI manifestations (9.2%), epididymitis (2.4%) and vascular involvement (1.4%). Patients with severe BD, defined as those with active major organ involvement (for example, meningoencephalitis or pulmonary artery aneurysm) were excluded.</p><p>&nbsp;</p><p>A total of 207 BD patients were randomised 1:1 to receive either apremilast 30&nbsp;mg twice daily (n&nbsp;=&nbsp;104) or placebo (n&nbsp;=&nbsp;103) for 12-weeks (placebo-controlled phase) and from weeks 12 to 64, all patients received apremilast 30&nbsp;mg twice daily (active treatment phase). Patients ranged in age from 19 to 72 years, with a mean age of 40 years. The mean duration of BD was 6.84 years. All patients had a history of recurrent oral ulcers with at least 2 oral ulcers at screening and randomisation: the mean baseline oral ulcer counts were 4.2 and 3.9 in the apremilast and placebo groups, respectively.</p><p>&nbsp;</p><p>The primary endpoint was the Area Under the Curve (AUC) for the number of oral ulcers from baseline through week 12. Secondary endpoints included other measures of oral ulcers: oral ulcer pain Visual Analog Scale (VAS), proportion of patients who are oral ulcer-free (complete response), time to onset of oral ulcer resolution, and proportion of patients achieving resolution of oral ulcers by week 6, and who remain oral ulcer free at every visit for at least 6 additional weeks during the 12-week placebo-controlled treatment phase. Other endpoints included Beh&ccedil;et&rsquo;s Syndrome Activity Score (BSAS), BD Current Activity Form (BDCAF), including the BD Current Activity Index (BDCAI) score, the Patient&rsquo;s Perception of Disease Activity, the Clinician&rsquo;s Overall Perception of Disease Activity and the BD Quality of Life Questionnaire (BD QoL).</p><p>&nbsp;</p><p><u>Measure of oral ulcers</u></p><p>&nbsp;</p><p>Apremilast 30&nbsp;mg twice daily resulted in significant improvement in oral ulcers as demonstrated by the AUC for the number of oral ulcers from baseline through week 12 (p&nbsp;&lt;&nbsp;0.0001), compared with placebo.</p><p>&nbsp;</p><p>Significant improvements in other measures of oral ulcers were demonstrated at week 12.</p><p>&nbsp;</p><p><strong>Table 6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Clinical response of oral ulcers at week 12 in RELIEF (ITT population)</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:653px"><tbody><tr><td><p><strong>&nbsp;</strong></p><p><strong>Endpoint<sup>a</sup></strong></p></td><td><p><strong>Placebo</strong></p><p><strong>N</strong>&nbsp;<strong>=</strong>&nbsp;<strong>103</strong></p></td><td><p><strong>Apremilast</strong></p><p><strong>30&nbsp;mg BID</strong></p><p><strong>N</strong>&nbsp;<strong>=</strong>&nbsp;<strong>104</strong></p></td></tr><tr><td><p>AUC<sup>b</sup> for the number of oral ulcers from baseline through week 12 (MI)</p></td><td><p>LS Mean</p><p>222.14</p></td><td><p>LS Mean</p><p>129.54</p></td></tr><tr><td><p>Change from baseline in the pain of oral ulcers as measured by VAS<sup>c</sup> at week 12 (MMRM)</p></td><td><p>LS Mean</p><p>-18.7</p></td><td><p>LS Mean</p><p>-42.7</p></td></tr><tr><td><p>Proportion of subjects achieving resolution of oral ulcers (oral ulcer-free) by week 6, and who remain oral ulcer free at every visit for at least 6 additional weeks during the 12-week placebo-controlled treatment phase</p></td><td><p>4.9%</p></td><td><p>29.8%</p></td></tr><tr><td><p>Median time (weeks) to oral ulcer resolution during the placebo-controlled treatment phase</p></td><td><p>8.1 weeks</p></td><td><p>2.1 weeks</p></td></tr><tr><td><p>Proportion of subjects with complete oral ulcer response at week 12 (NRI)</p></td><td><p>22.3%</p></td><td><p>52.9%</p></td></tr><tr><td><p>Proportion of subjects with partial oral ulcer response<sup>d</sup> at week 12 (NRI)</p></td><td><p>47.6%</p></td><td><p>76.0%</p></td></tr></tbody></table><p>ITT=intent to treat; LS=least squares; MI=multiple imputation; MMRM=mixed-effects model for repeated measures; NRI=non-responder imputation; BID=twice daily.</p><p><sup>a</sup> p-value &lt; 0.0001 for all apremilast vs. placebo</p><p><sup>b</sup> AUC = Area Under the Curve.</p><p><sup>c</sup> VAS&nbsp;=&nbsp;Visual Analog Scale; 0 = no pain, 100 = worst possible pain.</p><p><sup>d </sup>Partial oral ulcer response = number of oral ulcers reduced by &ge; 50% post-baseline (Exploratory analysis); nominal p-value &ndash; &lt; 0.0001</p><p>&nbsp;</p><p>Among 104 patients originally randomised to apremilast 30&nbsp;mg twice daily, 75 patients (approximately 72%) remained on this treatment at week 64. A significant reduction in the mean number of oral ulcers and oral ulcer pain was observed in the apremilast 30&nbsp;mg twice daily treatment group compared to the placebo treatment group at every visit, as early as week 1, through week 12 for number of oral ulcers (p&nbsp;&le;&nbsp;0.0015) and for oral ulcer pain (p&nbsp;&le;&nbsp;0.0035). Among patients who were continuously treated with apremilast and remained in the study, improvements in oral ulcers and reduction of oral ulcer pain were maintained through week 64 (figures 2 and 3).</p><p>&nbsp;</p><p>Among patients originally randomised to apremilast 30&nbsp;mg twice daily who remained in the study, the proportions of patients with a complete response and partial response of oral ulcers were maintained through week 64 (53.3% and 76.0% respectively).<strong> </strong></p><p><strong>Figure 2</strong><strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>Mean number of oral ulcers by time point through week 64 (ITT population; DAO)</strong></p><p><img src="data:image/png;base64,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" alt="" width="654" height="277" vspace="0" hspace="0" border="0" style="width:654px;height:277px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" /></p><p>ITT = Intent To Treat; DAO = Data As Observed.</p><p>APR 30 BID = apremilast 30&nbsp;mg twice daily.</p><p>Note: Placebo or APR 30&nbsp;mg BID indicates the treatment group in which patients were randomised. Placebo treatment group patients switched to APR 30 BID at week 12.</p><p>The follow-up time point was 4 weeks after patients completed week 64 or 4 weeks after patients discontinued treatment before week 64.</p><p><strong>Figure 3 </strong><strong>Mean change from baseline in oral ulcer pain on a visual analog scale by time point through week 64 (ITT population; DAO)</strong></p><p><strong>&nbsp;</strong><img src="data:image/png;base64,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" alt="" width="653" height="285" vspace="0" hspace="0" border="0" style="width:653px;height:285px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" /></p><p>APR 30 BID = apremilast twice daily; ITT = Intent-To-Treat; DAO = Data As Observed</p><p>Note: Placebo or APR 30&nbsp;mg BID indicates the treatment group in which patients were randomised. Placebo treatment group patients switched to APR 30 BID at week 12.</p><p>The follow-up time point was 4 weeks after patients completed week 64 or 4 weeks after patients discontinued treatment before week 64.</p><p>&nbsp;</p><p><u>Improvements in overall Beh&ccedil;et&rsquo;s disease activity</u></p><p><u>&nbsp;</u></p><p>Apremilast 30&nbsp;mg twice daily, compared with placebo, resulted in significant reduction in overall disease activity, as demonstrated by the mean change from baseline at week 12 in the BSAS (p&nbsp;&lt;&nbsp;0.0001) and the BDCAF (BDCAI, Patient&rsquo;s Perception of Disease Activity, and the Clinician&rsquo;s Overall Perception of Disease Activity; p-values &le;&nbsp;0.0335 for all three components).</p><p>&nbsp;</p><p>Among patients originally randomised to apremilast 30&nbsp;mg twice daily who remained in the study, improvements (mean change from baseline) in both the BSAS and the BDCAF were maintained at week 64.</p><p>&nbsp;</p><p><u>Improvements in quality of life</u></p><p><u>&nbsp;</u></p><p>Apremilast 30&nbsp;mg twice daily, compared with placebo, resulted in significantly greater improvement in Quality of Life (QoL) at week 12, as demonstrated by the BD QoL Questionnaire (p&nbsp;=&nbsp;0.0003).</p><p>&nbsp;</p><p>Among patients originally randomised to apremilast 30&nbsp;mg twice daily who remained in the study, improvement in BD QoL was maintained at week 64.</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>A</u><u>bsorption</u></p><p>Apremilast is well absorbed with an absolute oral bioavailability of approximately 73%, with peak plasma concentrations (C<sub>max</sub>) occurring at a median time (t<sub>max</sub>) of approximately 2.5 hours. Apremilast pharmacokinetics are linear, with a dose-proportional increase in systemic exposure in the dose range of 10 to 100&nbsp;mg daily. Accumulation is minimal when apremilast is administered once daily and approximately 53% in healthy subjects and 68% in patients with psoriasis when administered twice daily. Co‑administration with food does not alter the bioavailability therefore, apremilast can be administered with or without food.</p><p>&nbsp;</p><p><u>D</u><u>i</u><u>stribution</u></p><p>Human plasma protein binding of apremilast is approximately 68%. The mean apparent volume of distribution (Vd) is 87&nbsp;L, indicative of extravascular distribution.</p><p>&nbsp;</p><p><u>B</u><u>i</u><u>otransformation</u></p><p>Apremilast is extensively metabolised by both CYP and non-CYP mediated pathways including oxidation, hydrolysis, and conjugation, suggesting inhibition of a single clearance pathway is not likely to cause a marked drug-drug interaction. Oxidative metabolism of apremilast is primarily mediated by CYP3A4, with minor contributions from CYP1A2 and CYP2A6. Apremilast is the major circulating component following oral administration. Apremilast undergoes extensive metabolism with only 3% and 7% of the administered parent compound recovered in urine and faeces, respectively. The major circulating inactive metabolite is the glucuronide conjugate of <em>O</em>-demethylated apremilast (M12). Consistent with apremilast being a substrate of CYP3A4, apremilast exposure is decreased when administered concomitantly with rifampicin, a strong inducer of CYP3A4.</p><p>&nbsp;</p><p><em>I</em><em>n vitro</em>, apremilast is not an inhibitor or inducer of cytochrome P450 enzymes. Hence, apremilast co-administered with substrates of CYP enzymes is unlikely to affect the clearance and exposure of active substances that are metabolised by CYP enzymes.</p><p>&nbsp;</p><p><em>I</em><em>n vitro</em>, apremilast is a substrate, and a weak inhibitor of P-glycoprotein (IC<sub>50 </sub>&gt; 50&nbsp;&micro;M), however clinically relevant drug interactions mediated via P-gp are not expected to occur.</p><p>&nbsp;</p><p><em>I</em><em>n vitro</em>, apremilast has little to no inhibitory effect (IC<sub>50</sub> &gt; 10&nbsp;&micro;M) on Organic Anion Transporter (OAT)1 and OAT3, Organic Cation Transporter (OCT)2, Organic Anion Transporting Polypeptide (OATP)1B1 and OATP1B3, or breast cancer resistance protein (BCRP) and is not a substrate for these transporters. Hence, clinically relevant drug-drug interactions are unlikely when apremilast is co-administered with drugs that are substrates or inhibitors of these transporters.</p><p>&nbsp;</p><p><u>Elimination</u></p><p>The plasma clearance of apremilast is on average about 10&nbsp;L/hr in healthy subjects, with a terminal elimination half-life of approximately 9 hours. Following oral administration of radio-labelled apremilast, about 58% and 39% of the radioactivity is recovered in urine and faeces, respectively, with about 3% and 7% of the radioactive dose recovered as apremilast in urine and faeces, respectively.</p><p>&nbsp;</p><p><u>Elderly patients</u></p><p>Apremilast was studied in young and elderly healthy subjects. The exposure in elderly subjects (65 to 85 years of age) is about 13% higher in AUC and about 6% higher in C<sub>max</sub>&nbsp;for apremilast than that in young subjects (18 to 55 years of age). There is limited pharmacokinetic data in subjects over 75 years of age in clinical trials. No dosage adjustment is necessary for elderly patients.</p><p>&nbsp;</p><p><u>R</u><u>enal impairment</u></p><p>There is no meaningful difference in the PK of apremilast between mild or moderate renally impaired subjects and matched healthy subjects (N = 8 each). The results support that no dose adjustment is needed in patients with mild and moderate renal impairment. Apremilast dose should be reduced to 30&nbsp;mg once daily in patients with severe renal impairment (eGFR less than 30&nbsp;mL/min/1.73&nbsp;m<sup>2</sup> or CLcr&nbsp;&lt;&nbsp;30&nbsp;mL/min). In 8 subjects with severe renal impairment to whom a single dose of 30&nbsp;mg apremilast was administered, the AUC and C<sub>max</sub>&nbsp;of apremilast increased by approximately 89% and 42%, respectively.</p><p>&nbsp;</p><p><u>H</u><u>epatic impairment</u></p><p>The pharmacokinetics of apremilast and its major metabolite M12 are not affected by moderate or severe hepatic impairment. No dose adjustment is necessary for patients with hepatic impairment.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology and repeated dose toxicity. There is no evidence of immunotoxic, dermal irritation, or phototoxic potential.</p><p>&nbsp;</p><p><u>Fertility and early embryonic development</u></p><p>In a male mouse fertility study, apremilast at oral dosages of 1, 10, 25, and 50&nbsp;mg/kg/day produced no effects on male fertility; the No Observed Adverse Effect Level (NOAEL) for male fertility was greater than 50&nbsp;mg/kg/day 3-fold clinical exposure).</p><p>&nbsp;</p><p>In a combined female mouse fertility and embryo-foetal developmental toxicity study with oral dosages of 10, 20, 40, and 80&nbsp;mg/kg/day, a prolongation of oestrous cycles and increased time to mating were observed at 20&nbsp;mg/kg/day and above; despite this, all mice mated and pregnancy rates were unaffected. The No Observed Effect Level (NOEL) for female fertility was 10&nbsp;mg/kg/day (1.0-fold clinical exposure).</p><p>&nbsp;</p><p><u>Embryo-foetal development</u></p><p>In a combined female mouse fertility and embryo-foetal developmental toxicity study with oral dosages of 10, 20, 40, and 80&nbsp;mg/kg/day, absolute and/or relative heart weights of maternal animals were increased at 20, 40, and 80&nbsp;mg/kg/day. Increased numbers of early resorptions and reduced numbers of ossified tarsals were observed at 20, 40, and 80&nbsp;mg/kg/day. Reduced foetal weights and retarded ossification of the supraoccipital bone of the skull were observed at 40 and 80&nbsp;mg/kg/day. The maternal and developmental NOEL in the mouse was 10&nbsp;mg/kg/day (1.3-fold clinical exposure).</p><p>&nbsp;</p><p>In a monkey embryo-foetal developmental toxicity study, oral dosages of 20, 50, 200, and 1,000&nbsp;mg/kg/day resulted in a dose-related increase in prenatal loss (abortions) at dosages of 50&nbsp;mg/kg/day and above; no test article-related effect in prenatal loss was observed at 20&nbsp;mg/kg/day (1.4-fold clinical exposure).</p><p>&nbsp;</p><p><u>Pre- and post-natal development</u></p><p>In a pre- and postnatal study, apremilast was administered orally to pregnant female mice at dosages of 10, 80 and 300&nbsp;mg/kg/day from Gestation Day (GD) 6 to day 20 of lactation. Reductions in maternal body weight and weight gain, and one death associated with difficulty in delivering pups were observed at 300&nbsp;mg/kg/day. Physical signs of maternal toxicity associated with delivering pups were also observed in one mouse at each of 80 and 300&nbsp;mg/kg/day. Increased peri- and postnatal pup deaths and reduced pup body weights during the first week of lactation were observed at &ge; 80&nbsp;mg/kg/day (&ge; 4.0-fold clinical exposure). There were no apremilast-related effects on duration of pregnancy, number of pregnant mice at the end of the gestation period, number of mice that delivered a litter, or any developmental effects in the pups beyond postnatal day 7. It is likely that pup developmental effects observed during the first week of the postnatal period were related to the apremilast-related pup toxicity (decreased pup weight and viability) and/or lack of maternal care (higher incidence of no milk in the stomach of pups). All developmental effects were observed during the first week of the postnatal period; no apremilast-related effects were seen during the remaining pre- and post-weaning periods, including sexual maturation, behavioural, mating, fertility and uterine parameters. The NOEL in the mouse for maternal toxicity and F1 generation was 10&nbsp;mg/kg/day (1.3-fold clinical AUC).</p><p>&nbsp;</p><p><u>C</u><u>arcinogenicity studies</u></p><p>Carcinogenicity studies in mice and rats showed no evidence of carcinogenicity related to treatment with apremilast.</p><p>&nbsp;</p><p><u>G</u><u>enotoxicity studies</u></p><p>Apremilast is not genotoxic. Apremilast did not induce mutations in an Ames assay or chromosome aberrations in cultured human peripheral blood lymphocytes in the presence or absence of metabolic activation. Apremilast was not clastogenic in an <em>in vivo</em> mouse micronucleus assay at doses up to 2,000&nbsp;mg/kg/day.</p><p>&nbsp;</p><p><u>O</u><u>t</u><u>her studies</u></p><p>There is no evidence of immunotoxic, dermal irritation, or phototoxic potential.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&nbsp;</p><p>&nbsp;</p><p><strong>6.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; List of excipients</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="4" style="vertical-align:top"><p>Tablet core</p></td></tr><tr><td style="vertical-align:top"><p>Components</p></td><td style="vertical-align:top"><p>Otezla 10 mg</p></td><td style="vertical-align:top"><p>Otezla 20 mg</p></td><td style="vertical-align:top"><p>Otezla 30 mg</p></td></tr><tr><td style="vertical-align:top"><p>Cellulose microcrystalline</p></td><td style="vertical-align:top"><p>26.25 mg</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>52.5 mg</p></td><td style="vertical-align:top"><p>78.75 mg</p></td></tr><tr><td style="vertical-align:top"><p>Lactose monohydrate</p></td><td style="vertical-align:top"><p>60 mg</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>120 mg</p></td><td style="vertical-align:top"><p>180 mg</p></td></tr><tr><td style="vertical-align:top"><p>Croscarmellose sodium</p></td><td style="vertical-align:top"><p>3 mg</p></td><td style="vertical-align:top"><p>6 mg</p></td><td style="vertical-align:top"><p>9 mg</p></td></tr><tr><td style="vertical-align:top"><p>Magnesium stearate</p></td><td style="vertical-align:top"><p>0.75 mg</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>1.5 mg</p></td><td style="vertical-align:top"><p>2.25 mg</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="3" style="vertical-align:top"><p>Film-coating</p></td></tr><tr><td style="vertical-align:top"><p>Otezla 10 mg</p></td><td style="vertical-align:top"><p>Otezla 20 mg</p></td><td style="vertical-align:top"><p>Otezla 30 mg</p></td></tr><tr><td style="vertical-align:top"><p>Opadry II Pink (4mg)</p></td><td style="vertical-align:top"><p>Opadry II Borwn (8 mg)</p></td><td style="vertical-align:top"><p>Opadry II Beige (12 mg)</p></td></tr><tr><td style="vertical-align:top"><p>Poly (vinyl alcohol)</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Poly (vinyl alcohol)</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Poly (vinyl alcohol)</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Titanium dioxide (E171)</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Titanium dioxide (E171)</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Titanium dioxide (E171)</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Macrogol (3350)</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Macrogol (3350)</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Macrogol (3350)</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Talc</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Talc</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Talc</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Iron oxide red (E172)</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Iron oxide red (E172)</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Iron oxide red (E172)</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>Iron oxide yellow (E172)</p></td><td style="vertical-align:top"><p>Iron oxide yellow (E172)</p></td></tr><tr><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>Iron oxide black (E172)</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                3 years.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 30&deg;C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Otezla 10&nbsp;mg, 20&nbsp;mg, 30&nbsp;mg film-coated tablets</u> (initiation pack)</p><p><u>&nbsp;</u></p><p>PVC/aluminium foil blisters containing 27 film-coated tablets (4 &times;10&nbsp;mg, 4 &times; 20&nbsp;mg, 19 &times; 30&nbsp;mg).</p><p>&nbsp;</p><p><u>Otezla 30&nbsp;mg film-coated tablets</u></p><p>&nbsp;</p><p>PVC/aluminium foil blisters containing 14 film- coated tablets, in pack size of 56 tablets.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Amgen Europe B.V.
Minervum 7061
4817 ZK Breda
The Netherlands 

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                April 2020
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>